PubMed:10929004 JSONTXT

Annnotations TAB JSON ListView MergeView

    CL-cell

    {"project":"CL-cell","denotations":[{"id":"T1","span":{"begin":231,"end":243},"obj":"Cell"},{"id":"T2","span":{"begin":392,"end":407},"obj":"Cell"},{"id":"T3","span":{"begin":1907,"end":1922},"obj":"Cell"}],"attributes":[{"id":"A1","pred":"cl_id","subj":"T1","obj":"http://purl.obolibrary.org/obo/CL:0001064"},{"id":"A2","pred":"cl_id","subj":"T2","obj":"http://purl.obolibrary.org/obo/CL:0000066"},{"id":"A3","pred":"cl_id","subj":"T3","obj":"http://purl.obolibrary.org/obo/CL:0000066"}],"text":"Novel immunogenicity of Thomsen-Friedenreich disaccharide obtained by a molecular rotation on its carrier linkage.\nThe alpha-anomeric Galbeta1-3GalNAc, called Thomsen-Friedenreich disaccharide (TFD), is overexpressed in epithelial cancer cells by aberrant O-glycosylation. TFD is also the main ligand of Agaricus bisporus lectin (ABL), a reversible noncytotoxic inhibitor of proliferation of epithelial cell lines. In order to obtain anti-TFD antibody response with a fine carbohydrate-binding specificity similar to that of ABL, we designed an immunogen of TFD with a molecular rotation on its carrier linkage that exposes more GalNAc than Gal, since ABL recognizes GalNAc more than Gal in TFD. The synthesis was accomplished by C-6 oxidation of Gal from TFD or its alpha-benzyl derivative (BzlalphaTFD), followed by reductive amination between the C-6 aldehyde yielded and the available amine of protein. Mice immunized with TFD-KLH (keyhole limpet hemocyanin) or BzlalphaTFD-KLH produced antibodies which were then analyzed by ELISA against several target antigens. Both immunogens raised anti-KLH antibody titers; however, TFD-KLH did not raise anti-TFD antibodies showing low TFD immunogenicity. In contrast, BzlalphaTFD-KLH gave much higher anti-TFD antibody response, indicating that benzyl residue helps improve anti-carbohydrate immune response. When IgG and IgM anti-TFD antibodies were analyzed by competitive ELISA using TFD-related carbohydrates as inhibitors, a high specificity to TFD as well as an enhanced binding to GalNAc over Gal were observed. The axial C-4 hydroxyl group of GalNAc interacted with IgG anti-TFD antibody, as evidenced by the lack of inhibitory activity of GlcNAc in contrast to GalNAc. These findings indicate that the anti-TFD antibodies have fine carbohydrate-binding specificity more similar to ABL than to other TFD-binding proteins that stimulate proliferation of epithelial cell lines."}

    sentences

    {"project":"sentences","denotations":[{"id":"TextSentencer_T1","span":{"begin":0,"end":114},"obj":"Sentence"},{"id":"TextSentencer_T2","span":{"begin":115,"end":272},"obj":"Sentence"},{"id":"TextSentencer_T3","span":{"begin":273,"end":414},"obj":"Sentence"},{"id":"TextSentencer_T4","span":{"begin":415,"end":695},"obj":"Sentence"},{"id":"TextSentencer_T5","span":{"begin":696,"end":906},"obj":"Sentence"},{"id":"TextSentencer_T6","span":{"begin":907,"end":1068},"obj":"Sentence"},{"id":"TextSentencer_T7","span":{"begin":1069,"end":1200},"obj":"Sentence"},{"id":"TextSentencer_T8","span":{"begin":1201,"end":1354},"obj":"Sentence"},{"id":"TextSentencer_T9","span":{"begin":1355,"end":1564},"obj":"Sentence"},{"id":"TextSentencer_T10","span":{"begin":1565,"end":1723},"obj":"Sentence"},{"id":"TextSentencer_T11","span":{"begin":1724,"end":1929},"obj":"Sentence"},{"id":"T1","span":{"begin":0,"end":114},"obj":"Sentence"},{"id":"T2","span":{"begin":115,"end":272},"obj":"Sentence"},{"id":"T3","span":{"begin":273,"end":414},"obj":"Sentence"},{"id":"T4","span":{"begin":415,"end":695},"obj":"Sentence"},{"id":"T5","span":{"begin":696,"end":906},"obj":"Sentence"},{"id":"T6","span":{"begin":907,"end":1068},"obj":"Sentence"},{"id":"T7","span":{"begin":1069,"end":1200},"obj":"Sentence"},{"id":"T8","span":{"begin":1201,"end":1354},"obj":"Sentence"},{"id":"T9","span":{"begin":1355,"end":1564},"obj":"Sentence"},{"id":"T10","span":{"begin":1565,"end":1723},"obj":"Sentence"},{"id":"T11","span":{"begin":1724,"end":1929},"obj":"Sentence"},{"id":"T1","span":{"begin":0,"end":114},"obj":"Sentence"},{"id":"T2","span":{"begin":115,"end":272},"obj":"Sentence"},{"id":"T3","span":{"begin":273,"end":414},"obj":"Sentence"},{"id":"T4","span":{"begin":415,"end":695},"obj":"Sentence"},{"id":"T5","span":{"begin":696,"end":906},"obj":"Sentence"},{"id":"T6","span":{"begin":907,"end":1068},"obj":"Sentence"},{"id":"T7","span":{"begin":1069,"end":1200},"obj":"Sentence"},{"id":"T8","span":{"begin":1201,"end":1354},"obj":"Sentence"},{"id":"T9","span":{"begin":1355,"end":1564},"obj":"Sentence"},{"id":"T10","span":{"begin":1565,"end":1723},"obj":"Sentence"},{"id":"T11","span":{"begin":1724,"end":1929},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"Novel immunogenicity of Thomsen-Friedenreich disaccharide obtained by a molecular rotation on its carrier linkage.\nThe alpha-anomeric Galbeta1-3GalNAc, called Thomsen-Friedenreich disaccharide (TFD), is overexpressed in epithelial cancer cells by aberrant O-glycosylation. TFD is also the main ligand of Agaricus bisporus lectin (ABL), a reversible noncytotoxic inhibitor of proliferation of epithelial cell lines. In order to obtain anti-TFD antibody response with a fine carbohydrate-binding specificity similar to that of ABL, we designed an immunogen of TFD with a molecular rotation on its carrier linkage that exposes more GalNAc than Gal, since ABL recognizes GalNAc more than Gal in TFD. The synthesis was accomplished by C-6 oxidation of Gal from TFD or its alpha-benzyl derivative (BzlalphaTFD), followed by reductive amination between the C-6 aldehyde yielded and the available amine of protein. Mice immunized with TFD-KLH (keyhole limpet hemocyanin) or BzlalphaTFD-KLH produced antibodies which were then analyzed by ELISA against several target antigens. Both immunogens raised anti-KLH antibody titers; however, TFD-KLH did not raise anti-TFD antibodies showing low TFD immunogenicity. In contrast, BzlalphaTFD-KLH gave much higher anti-TFD antibody response, indicating that benzyl residue helps improve anti-carbohydrate immune response. When IgG and IgM anti-TFD antibodies were analyzed by competitive ELISA using TFD-related carbohydrates as inhibitors, a high specificity to TFD as well as an enhanced binding to GalNAc over Gal were observed. The axial C-4 hydroxyl group of GalNAc interacted with IgG anti-TFD antibody, as evidenced by the lack of inhibitory activity of GlcNAc in contrast to GalNAc. These findings indicate that the anti-TFD antibodies have fine carbohydrate-binding specificity more similar to ABL than to other TFD-binding proteins that stimulate proliferation of epithelial cell lines."}

    PubmedHPO

    {"project":"PubmedHPO","denotations":[{"id":"T1","span":{"begin":231,"end":237},"obj":"HP_0002664"}],"text":"Novel immunogenicity of Thomsen-Friedenreich disaccharide obtained by a molecular rotation on its carrier linkage.\nThe alpha-anomeric Galbeta1-3GalNAc, called Thomsen-Friedenreich disaccharide (TFD), is overexpressed in epithelial cancer cells by aberrant O-glycosylation. TFD is also the main ligand of Agaricus bisporus lectin (ABL), a reversible noncytotoxic inhibitor of proliferation of epithelial cell lines. In order to obtain anti-TFD antibody response with a fine carbohydrate-binding specificity similar to that of ABL, we designed an immunogen of TFD with a molecular rotation on its carrier linkage that exposes more GalNAc than Gal, since ABL recognizes GalNAc more than Gal in TFD. The synthesis was accomplished by C-6 oxidation of Gal from TFD or its alpha-benzyl derivative (BzlalphaTFD), followed by reductive amination between the C-6 aldehyde yielded and the available amine of protein. Mice immunized with TFD-KLH (keyhole limpet hemocyanin) or BzlalphaTFD-KLH produced antibodies which were then analyzed by ELISA against several target antigens. Both immunogens raised anti-KLH antibody titers; however, TFD-KLH did not raise anti-TFD antibodies showing low TFD immunogenicity. In contrast, BzlalphaTFD-KLH gave much higher anti-TFD antibody response, indicating that benzyl residue helps improve anti-carbohydrate immune response. When IgG and IgM anti-TFD antibodies were analyzed by competitive ELISA using TFD-related carbohydrates as inhibitors, a high specificity to TFD as well as an enhanced binding to GalNAc over Gal were observed. The axial C-4 hydroxyl group of GalNAc interacted with IgG anti-TFD antibody, as evidenced by the lack of inhibitory activity of GlcNAc in contrast to GalNAc. These findings indicate that the anti-TFD antibodies have fine carbohydrate-binding specificity more similar to ABL than to other TFD-binding proteins that stimulate proliferation of epithelial cell lines."}

    GlycoBiology-FMA

    {"project":"GlycoBiology-FMA","denotations":[{"id":"_T1","span":{"begin":45,"end":57},"obj":"FMAID:82744"},{"id":"_T2","span":{"begin":45,"end":57},"obj":"FMAID:196733"},{"id":"_T3","span":{"begin":180,"end":192},"obj":"FMAID:82744"},{"id":"_T4","span":{"begin":180,"end":192},"obj":"FMAID:196733"},{"id":"_T5","span":{"begin":220,"end":243},"obj":"FMAID:164922"},{"id":"_T6","span":{"begin":220,"end":243},"obj":"FMAID:66768"},{"id":"_T7","span":{"begin":238,"end":243},"obj":"FMAID:169002"},{"id":"_T8","span":{"begin":238,"end":243},"obj":"FMAID:68646"},{"id":"_T9","span":{"begin":289,"end":293},"obj":"FMAID:214734"},{"id":"_T10","span":{"begin":392,"end":407},"obj":"FMAID:69074"},{"id":"_T11","span":{"begin":392,"end":407},"obj":"FMAID:165528"},{"id":"_T12","span":{"begin":392,"end":407},"obj":"FMAID:67559"},{"id":"_T13","span":{"begin":392,"end":407},"obj":"FMAID:169653"},{"id":"_T14","span":{"begin":392,"end":407},"obj":"FMAID:66768"},{"id":"_T15","span":{"begin":392,"end":407},"obj":"FMAID:169652"},{"id":"_T16","span":{"begin":392,"end":407},"obj":"FMAID:83514"},{"id":"_T17","span":{"begin":392,"end":407},"obj":"FMAID:67799"},{"id":"_T18","span":{"begin":392,"end":407},"obj":"FMAID:165731"},{"id":"_T19","span":{"begin":392,"end":407},"obj":"FMAID:164922"},{"id":"_T20","span":{"begin":392,"end":407},"obj":"FMAID:197786"},{"id":"_T21","span":{"begin":392,"end":407},"obj":"FMAID:69075"},{"id":"_T22","span":{"begin":443,"end":451},"obj":"FMAID:167180"},{"id":"_T23","span":{"begin":473,"end":485},"obj":"FMAID:197276"},{"id":"_T24","span":{"begin":473,"end":485},"obj":"FMAID:82737"},{"id":"_T25","span":{"begin":898,"end":905},"obj":"FMAID:165447"},{"id":"_T26","span":{"begin":898,"end":905},"obj":"FMAID:67257"},{"id":"_T27","span":{"begin":991,"end":1001},"obj":"FMAID:167180"},{"id":"_T28","span":{"begin":1101,"end":1109},"obj":"FMAID:167180"},{"id":"_T29","span":{"begin":1158,"end":1168},"obj":"FMAID:167180"},{"id":"_T30","span":{"begin":1256,"end":1264},"obj":"FMAID:167180"},{"id":"_T31","span":{"begin":1325,"end":1337},"obj":"FMAID:197276"},{"id":"_T32","span":{"begin":1325,"end":1337},"obj":"FMAID:82737"},{"id":"_T33","span":{"begin":1360,"end":1363},"obj":"FMAID:167179"},{"id":"_T34","span":{"begin":1368,"end":1371},"obj":"FMAID:167182"},{"id":"_T35","span":{"begin":1381,"end":1391},"obj":"FMAID:167180"},{"id":"_T36","span":{"begin":1445,"end":1458},"obj":"FMAID:82737"},{"id":"_T37","span":{"begin":1445,"end":1458},"obj":"FMAID:197276"},{"id":"_T38","span":{"begin":1569,"end":1574},"obj":"FMAID:179284"},{"id":"_T39","span":{"begin":1569,"end":1574},"obj":"FMAID:74547"},{"id":"_T40","span":{"begin":1620,"end":1623},"obj":"FMAID:167179"},{"id":"_T41","span":{"begin":1633,"end":1641},"obj":"FMAID:167180"},{"id":"_T42","span":{"begin":1766,"end":1776},"obj":"FMAID:167180"},{"id":"_T43","span":{"begin":1787,"end":1799},"obj":"FMAID:82737"},{"id":"_T44","span":{"begin":1787,"end":1799},"obj":"FMAID:197276"},{"id":"_T45","span":{"begin":1866,"end":1874},"obj":"FMAID:67257"},{"id":"_T46","span":{"begin":1866,"end":1874},"obj":"FMAID:165447"},{"id":"_T47","span":{"begin":1907,"end":1922},"obj":"FMAID:83514"},{"id":"_T48","span":{"begin":1907,"end":1922},"obj":"FMAID:67559"},{"id":"_T49","span":{"begin":1907,"end":1922},"obj":"FMAID:165528"},{"id":"_T50","span":{"begin":1907,"end":1922},"obj":"FMAID:66768"},{"id":"_T51","span":{"begin":1907,"end":1922},"obj":"FMAID:164922"},{"id":"_T52","span":{"begin":1907,"end":1922},"obj":"FMAID:69075"},{"id":"_T53","span":{"begin":1907,"end":1922},"obj":"FMAID:165731"},{"id":"_T54","span":{"begin":1907,"end":1922},"obj":"FMAID:67799"},{"id":"_T55","span":{"begin":1907,"end":1922},"obj":"FMAID:169653"},{"id":"_T56","span":{"begin":1907,"end":1922},"obj":"FMAID:69074"},{"id":"_T57","span":{"begin":1907,"end":1922},"obj":"FMAID:169652"},{"id":"_T58","span":{"begin":1907,"end":1922},"obj":"FMAID:197786"}],"namespaces":[{"prefix":"FMAID","uri":"http://purl.org/sig/ont/fma/fma"}],"text":"Novel immunogenicity of Thomsen-Friedenreich disaccharide obtained by a molecular rotation on its carrier linkage.\nThe alpha-anomeric Galbeta1-3GalNAc, called Thomsen-Friedenreich disaccharide (TFD), is overexpressed in epithelial cancer cells by aberrant O-glycosylation. TFD is also the main ligand of Agaricus bisporus lectin (ABL), a reversible noncytotoxic inhibitor of proliferation of epithelial cell lines. In order to obtain anti-TFD antibody response with a fine carbohydrate-binding specificity similar to that of ABL, we designed an immunogen of TFD with a molecular rotation on its carrier linkage that exposes more GalNAc than Gal, since ABL recognizes GalNAc more than Gal in TFD. The synthesis was accomplished by C-6 oxidation of Gal from TFD or its alpha-benzyl derivative (BzlalphaTFD), followed by reductive amination between the C-6 aldehyde yielded and the available amine of protein. Mice immunized with TFD-KLH (keyhole limpet hemocyanin) or BzlalphaTFD-KLH produced antibodies which were then analyzed by ELISA against several target antigens. Both immunogens raised anti-KLH antibody titers; however, TFD-KLH did not raise anti-TFD antibodies showing low TFD immunogenicity. In contrast, BzlalphaTFD-KLH gave much higher anti-TFD antibody response, indicating that benzyl residue helps improve anti-carbohydrate immune response. When IgG and IgM anti-TFD antibodies were analyzed by competitive ELISA using TFD-related carbohydrates as inhibitors, a high specificity to TFD as well as an enhanced binding to GalNAc over Gal were observed. The axial C-4 hydroxyl group of GalNAc interacted with IgG anti-TFD antibody, as evidenced by the lack of inhibitory activity of GlcNAc in contrast to GalNAc. These findings indicate that the anti-TFD antibodies have fine carbohydrate-binding specificity more similar to ABL than to other TFD-binding proteins that stimulate proliferation of epithelial cell lines."}

    uniprot-human

    {"project":"uniprot-human","denotations":[{"id":"T1","span":{"begin":330,"end":333},"obj":"http://www.uniprot.org/uniprot/P00519"},{"id":"T2","span":{"begin":525,"end":528},"obj":"http://www.uniprot.org/uniprot/P00519"},{"id":"T3","span":{"begin":652,"end":655},"obj":"http://www.uniprot.org/uniprot/P00519"},{"id":"T4","span":{"begin":1836,"end":1839},"obj":"http://www.uniprot.org/uniprot/P00519"}],"text":"Novel immunogenicity of Thomsen-Friedenreich disaccharide obtained by a molecular rotation on its carrier linkage.\nThe alpha-anomeric Galbeta1-3GalNAc, called Thomsen-Friedenreich disaccharide (TFD), is overexpressed in epithelial cancer cells by aberrant O-glycosylation. TFD is also the main ligand of Agaricus bisporus lectin (ABL), a reversible noncytotoxic inhibitor of proliferation of epithelial cell lines. In order to obtain anti-TFD antibody response with a fine carbohydrate-binding specificity similar to that of ABL, we designed an immunogen of TFD with a molecular rotation on its carrier linkage that exposes more GalNAc than Gal, since ABL recognizes GalNAc more than Gal in TFD. The synthesis was accomplished by C-6 oxidation of Gal from TFD or its alpha-benzyl derivative (BzlalphaTFD), followed by reductive amination between the C-6 aldehyde yielded and the available amine of protein. Mice immunized with TFD-KLH (keyhole limpet hemocyanin) or BzlalphaTFD-KLH produced antibodies which were then analyzed by ELISA against several target antigens. Both immunogens raised anti-KLH antibody titers; however, TFD-KLH did not raise anti-TFD antibodies showing low TFD immunogenicity. In contrast, BzlalphaTFD-KLH gave much higher anti-TFD antibody response, indicating that benzyl residue helps improve anti-carbohydrate immune response. When IgG and IgM anti-TFD antibodies were analyzed by competitive ELISA using TFD-related carbohydrates as inhibitors, a high specificity to TFD as well as an enhanced binding to GalNAc over Gal were observed. The axial C-4 hydroxyl group of GalNAc interacted with IgG anti-TFD antibody, as evidenced by the lack of inhibitory activity of GlcNAc in contrast to GalNAc. These findings indicate that the anti-TFD antibodies have fine carbohydrate-binding specificity more similar to ABL than to other TFD-binding proteins that stimulate proliferation of epithelial cell lines."}

    GlycoBiology-NCBITAXON

    {"project":"GlycoBiology-NCBITAXON","denotations":[{"id":"T1","span":{"begin":231,"end":237},"obj":"http://purl.bioontology.org/ontology/NCBITAXON/6754"},{"id":"T2","span":{"begin":238,"end":243},"obj":"http://purl.bioontology.org/ontology/STY/T025"},{"id":"T3","span":{"begin":1437,"end":1444},"obj":"http://purl.bioontology.org/ontology/NCBITAXON/353209"},{"id":"T4","span":{"begin":1588,"end":1593},"obj":"http://purl.bioontology.org/ontology/STY/T096"},{"id":"T5","span":{"begin":1730,"end":1738},"obj":"http://purl.bioontology.org/ontology/STY/T033"}],"text":"Novel immunogenicity of Thomsen-Friedenreich disaccharide obtained by a molecular rotation on its carrier linkage.\nThe alpha-anomeric Galbeta1-3GalNAc, called Thomsen-Friedenreich disaccharide (TFD), is overexpressed in epithelial cancer cells by aberrant O-glycosylation. TFD is also the main ligand of Agaricus bisporus lectin (ABL), a reversible noncytotoxic inhibitor of proliferation of epithelial cell lines. In order to obtain anti-TFD antibody response with a fine carbohydrate-binding specificity similar to that of ABL, we designed an immunogen of TFD with a molecular rotation on its carrier linkage that exposes more GalNAc than Gal, since ABL recognizes GalNAc more than Gal in TFD. The synthesis was accomplished by C-6 oxidation of Gal from TFD or its alpha-benzyl derivative (BzlalphaTFD), followed by reductive amination between the C-6 aldehyde yielded and the available amine of protein. Mice immunized with TFD-KLH (keyhole limpet hemocyanin) or BzlalphaTFD-KLH produced antibodies which were then analyzed by ELISA against several target antigens. Both immunogens raised anti-KLH antibody titers; however, TFD-KLH did not raise anti-TFD antibodies showing low TFD immunogenicity. In contrast, BzlalphaTFD-KLH gave much higher anti-TFD antibody response, indicating that benzyl residue helps improve anti-carbohydrate immune response. When IgG and IgM anti-TFD antibodies were analyzed by competitive ELISA using TFD-related carbohydrates as inhibitors, a high specificity to TFD as well as an enhanced binding to GalNAc over Gal were observed. The axial C-4 hydroxyl group of GalNAc interacted with IgG anti-TFD antibody, as evidenced by the lack of inhibitory activity of GlcNAc in contrast to GalNAc. These findings indicate that the anti-TFD antibodies have fine carbohydrate-binding specificity more similar to ABL than to other TFD-binding proteins that stimulate proliferation of epithelial cell lines."}

    GO-BP

    {"project":"GO-BP","denotations":[{"id":"T1","span":{"begin":258,"end":271},"obj":"http://purl.obolibrary.org/obo/GO_0070085"},{"id":"T2","span":{"begin":375,"end":407},"obj":"http://purl.obolibrary.org/obo/GO_0050679"},{"id":"T3","span":{"begin":1890,"end":1922},"obj":"http://purl.obolibrary.org/obo/GO_0050679"},{"id":"T4","span":{"begin":375,"end":407},"obj":"http://purl.obolibrary.org/obo/GO_0050673"},{"id":"T5","span":{"begin":1890,"end":1922},"obj":"http://purl.obolibrary.org/obo/GO_0050673"},{"id":"T6","span":{"begin":375,"end":407},"obj":"http://purl.obolibrary.org/obo/GO_0050680"},{"id":"T7","span":{"begin":1890,"end":1922},"obj":"http://purl.obolibrary.org/obo/GO_0050680"},{"id":"T8","span":{"begin":375,"end":407},"obj":"http://purl.obolibrary.org/obo/GO_0097166"},{"id":"T9","span":{"begin":1890,"end":1922},"obj":"http://purl.obolibrary.org/obo/GO_0097166"},{"id":"T10","span":{"begin":375,"end":407},"obj":"http://purl.obolibrary.org/obo/GO_0050678"},{"id":"T11","span":{"begin":1890,"end":1922},"obj":"http://purl.obolibrary.org/obo/GO_0050678"},{"id":"T12","span":{"begin":1880,"end":1922},"obj":"http://purl.obolibrary.org/obo/GO_0050679"},{"id":"T13","span":{"begin":700,"end":709},"obj":"http://purl.obolibrary.org/obo/GO_0009058"},{"id":"T14","span":{"begin":951,"end":961},"obj":"http://purl.obolibrary.org/obo/GO_0005344"},{"id":"T15","span":{"begin":1338,"end":1353},"obj":"http://purl.obolibrary.org/obo/GO_0006955"},{"id":"T16","span":{"begin":1858,"end":1889},"obj":"http://purl.obolibrary.org/obo/GO_0032092"}],"text":"Novel immunogenicity of Thomsen-Friedenreich disaccharide obtained by a molecular rotation on its carrier linkage.\nThe alpha-anomeric Galbeta1-3GalNAc, called Thomsen-Friedenreich disaccharide (TFD), is overexpressed in epithelial cancer cells by aberrant O-glycosylation. TFD is also the main ligand of Agaricus bisporus lectin (ABL), a reversible noncytotoxic inhibitor of proliferation of epithelial cell lines. In order to obtain anti-TFD antibody response with a fine carbohydrate-binding specificity similar to that of ABL, we designed an immunogen of TFD with a molecular rotation on its carrier linkage that exposes more GalNAc than Gal, since ABL recognizes GalNAc more than Gal in TFD. The synthesis was accomplished by C-6 oxidation of Gal from TFD or its alpha-benzyl derivative (BzlalphaTFD), followed by reductive amination between the C-6 aldehyde yielded and the available amine of protein. Mice immunized with TFD-KLH (keyhole limpet hemocyanin) or BzlalphaTFD-KLH produced antibodies which were then analyzed by ELISA against several target antigens. Both immunogens raised anti-KLH antibody titers; however, TFD-KLH did not raise anti-TFD antibodies showing low TFD immunogenicity. In contrast, BzlalphaTFD-KLH gave much higher anti-TFD antibody response, indicating that benzyl residue helps improve anti-carbohydrate immune response. When IgG and IgM anti-TFD antibodies were analyzed by competitive ELISA using TFD-related carbohydrates as inhibitors, a high specificity to TFD as well as an enhanced binding to GalNAc over Gal were observed. The axial C-4 hydroxyl group of GalNAc interacted with IgG anti-TFD antibody, as evidenced by the lack of inhibitory activity of GlcNAc in contrast to GalNAc. These findings indicate that the anti-TFD antibodies have fine carbohydrate-binding specificity more similar to ABL than to other TFD-binding proteins that stimulate proliferation of epithelial cell lines."}

    GO-MF

    {"project":"GO-MF","denotations":[{"id":"T1","span":{"begin":294,"end":300},"obj":"http://purl.obolibrary.org/obo/GO_0005488"},{"id":"T2","span":{"begin":443,"end":451},"obj":"http://purl.obolibrary.org/obo/GO_0003823"},{"id":"T3","span":{"begin":1101,"end":1109},"obj":"http://purl.obolibrary.org/obo/GO_0003823"},{"id":"T4","span":{"begin":1256,"end":1264},"obj":"http://purl.obolibrary.org/obo/GO_0003823"},{"id":"T5","span":{"begin":991,"end":1001},"obj":"http://purl.obolibrary.org/obo/GO_0003823"},{"id":"T6","span":{"begin":1158,"end":1168},"obj":"http://purl.obolibrary.org/obo/GO_0003823"},{"id":"T7","span":{"begin":1381,"end":1391},"obj":"http://purl.obolibrary.org/obo/GO_0003823"},{"id":"T8","span":{"begin":1766,"end":1776},"obj":"http://purl.obolibrary.org/obo/GO_0003823"},{"id":"T9","span":{"begin":473,"end":493},"obj":"http://purl.obolibrary.org/obo/GO_0030246"},{"id":"T10","span":{"begin":1787,"end":1807},"obj":"http://purl.obolibrary.org/obo/GO_0030246"},{"id":"T11","span":{"begin":486,"end":493},"obj":"http://purl.obolibrary.org/obo/GO_0070026"},{"id":"T12","span":{"begin":1523,"end":1530},"obj":"http://purl.obolibrary.org/obo/GO_0070026"},{"id":"T13","span":{"begin":1800,"end":1807},"obj":"http://purl.obolibrary.org/obo/GO_0070026"},{"id":"T14","span":{"begin":1858,"end":1865},"obj":"http://purl.obolibrary.org/obo/GO_0070026"},{"id":"T15","span":{"begin":486,"end":493},"obj":"http://purl.obolibrary.org/obo/GO_0003680"},{"id":"T16","span":{"begin":1523,"end":1530},"obj":"http://purl.obolibrary.org/obo/GO_0003680"},{"id":"T17","span":{"begin":1800,"end":1807},"obj":"http://purl.obolibrary.org/obo/GO_0003680"},{"id":"T18","span":{"begin":1858,"end":1865},"obj":"http://purl.obolibrary.org/obo/GO_0003680"},{"id":"T19","span":{"begin":486,"end":493},"obj":"http://purl.obolibrary.org/obo/GO_0017091"},{"id":"T20","span":{"begin":1523,"end":1530},"obj":"http://purl.obolibrary.org/obo/GO_0017091"},{"id":"T21","span":{"begin":1800,"end":1807},"obj":"http://purl.obolibrary.org/obo/GO_0017091"},{"id":"T22","span":{"begin":1858,"end":1865},"obj":"http://purl.obolibrary.org/obo/GO_0017091"},{"id":"T23","span":{"begin":486,"end":493},"obj":"http://purl.obolibrary.org/obo/GO_0005488"},{"id":"T24","span":{"begin":1523,"end":1530},"obj":"http://purl.obolibrary.org/obo/GO_0005488"},{"id":"T25","span":{"begin":1800,"end":1807},"obj":"http://purl.obolibrary.org/obo/GO_0005488"},{"id":"T26","span":{"begin":1858,"end":1865},"obj":"http://purl.obolibrary.org/obo/GO_0005488"},{"id":"T27","span":{"begin":1514,"end":1530},"obj":"http://purl.obolibrary.org/obo/GO_0035326"},{"id":"T28","span":{"begin":1858,"end":1874},"obj":"http://purl.obolibrary.org/obo/GO_0005515"}],"text":"Novel immunogenicity of Thomsen-Friedenreich disaccharide obtained by a molecular rotation on its carrier linkage.\nThe alpha-anomeric Galbeta1-3GalNAc, called Thomsen-Friedenreich disaccharide (TFD), is overexpressed in epithelial cancer cells by aberrant O-glycosylation. TFD is also the main ligand of Agaricus bisporus lectin (ABL), a reversible noncytotoxic inhibitor of proliferation of epithelial cell lines. In order to obtain anti-TFD antibody response with a fine carbohydrate-binding specificity similar to that of ABL, we designed an immunogen of TFD with a molecular rotation on its carrier linkage that exposes more GalNAc than Gal, since ABL recognizes GalNAc more than Gal in TFD. The synthesis was accomplished by C-6 oxidation of Gal from TFD or its alpha-benzyl derivative (BzlalphaTFD), followed by reductive amination between the C-6 aldehyde yielded and the available amine of protein. Mice immunized with TFD-KLH (keyhole limpet hemocyanin) or BzlalphaTFD-KLH produced antibodies which were then analyzed by ELISA against several target antigens. Both immunogens raised anti-KLH antibody titers; however, TFD-KLH did not raise anti-TFD antibodies showing low TFD immunogenicity. In contrast, BzlalphaTFD-KLH gave much higher anti-TFD antibody response, indicating that benzyl residue helps improve anti-carbohydrate immune response. When IgG and IgM anti-TFD antibodies were analyzed by competitive ELISA using TFD-related carbohydrates as inhibitors, a high specificity to TFD as well as an enhanced binding to GalNAc over Gal were observed. The axial C-4 hydroxyl group of GalNAc interacted with IgG anti-TFD antibody, as evidenced by the lack of inhibitory activity of GlcNAc in contrast to GalNAc. These findings indicate that the anti-TFD antibodies have fine carbohydrate-binding specificity more similar to ABL than to other TFD-binding proteins that stimulate proliferation of epithelial cell lines."}

    GO-CC

    {"project":"GO-CC","denotations":[{"id":"T1","span":{"begin":238,"end":243},"obj":"http://purl.obolibrary.org/obo/GO_0005623"},{"id":"T2","span":{"begin":403,"end":407},"obj":"http://purl.obolibrary.org/obo/GO_0005623"},{"id":"T3","span":{"begin":1918,"end":1922},"obj":"http://purl.obolibrary.org/obo/GO_0005623"}],"text":"Novel immunogenicity of Thomsen-Friedenreich disaccharide obtained by a molecular rotation on its carrier linkage.\nThe alpha-anomeric Galbeta1-3GalNAc, called Thomsen-Friedenreich disaccharide (TFD), is overexpressed in epithelial cancer cells by aberrant O-glycosylation. TFD is also the main ligand of Agaricus bisporus lectin (ABL), a reversible noncytotoxic inhibitor of proliferation of epithelial cell lines. In order to obtain anti-TFD antibody response with a fine carbohydrate-binding specificity similar to that of ABL, we designed an immunogen of TFD with a molecular rotation on its carrier linkage that exposes more GalNAc than Gal, since ABL recognizes GalNAc more than Gal in TFD. The synthesis was accomplished by C-6 oxidation of Gal from TFD or its alpha-benzyl derivative (BzlalphaTFD), followed by reductive amination between the C-6 aldehyde yielded and the available amine of protein. Mice immunized with TFD-KLH (keyhole limpet hemocyanin) or BzlalphaTFD-KLH produced antibodies which were then analyzed by ELISA against several target antigens. Both immunogens raised anti-KLH antibody titers; however, TFD-KLH did not raise anti-TFD antibodies showing low TFD immunogenicity. In contrast, BzlalphaTFD-KLH gave much higher anti-TFD antibody response, indicating that benzyl residue helps improve anti-carbohydrate immune response. When IgG and IgM anti-TFD antibodies were analyzed by competitive ELISA using TFD-related carbohydrates as inhibitors, a high specificity to TFD as well as an enhanced binding to GalNAc over Gal were observed. The axial C-4 hydroxyl group of GalNAc interacted with IgG anti-TFD antibody, as evidenced by the lack of inhibitory activity of GlcNAc in contrast to GalNAc. These findings indicate that the anti-TFD antibodies have fine carbohydrate-binding specificity more similar to ABL than to other TFD-binding proteins that stimulate proliferation of epithelial cell lines."}

    EDAM-topics

    {"project":"EDAM-topics","denotations":[{"id":"T1","span":{"begin":6,"end":20},"obj":"http://edamontology.org/topic_2830"},{"id":"T2","span":{"begin":106,"end":113},"obj":"http://edamontology.org/topic_0102"},{"id":"T3","span":{"begin":231,"end":237},"obj":"http://edamontology.org/topic_2640"},{"id":"T4","span":{"begin":473,"end":485},"obj":"http://edamontology.org/topic_0152"},{"id":"T5","span":{"begin":545,"end":554},"obj":"http://edamontology.org/topic_2830"},{"id":"T6","span":{"begin":603,"end":610},"obj":"http://edamontology.org/topic_0102"},{"id":"T7","span":{"begin":898,"end":905},"obj":"http://edamontology.org/topic_0078"},{"id":"T8","span":{"begin":1052,"end":1058},"obj":"http://edamontology.org/topic_0154"},{"id":"T9","span":{"begin":1059,"end":1067},"obj":"http://edamontology.org/topic_2830"},{"id":"T10","span":{"begin":1074,"end":1084},"obj":"http://edamontology.org/topic_2830"},{"id":"T11","span":{"begin":1185,"end":1199},"obj":"http://edamontology.org/topic_2830"},{"id":"T12","span":{"begin":1325,"end":1337},"obj":"http://edamontology.org/topic_0152"},{"id":"T13","span":{"begin":1445,"end":1458},"obj":"http://edamontology.org/topic_0152"},{"id":"T14","span":{"begin":1604,"end":1614},"obj":"http://edamontology.org/topic_0602"},{"id":"T15","span":{"begin":1787,"end":1799},"obj":"http://edamontology.org/topic_0152"},{"id":"T16","span":{"begin":1866,"end":1874},"obj":"http://edamontology.org/topic_0078"}],"text":"Novel immunogenicity of Thomsen-Friedenreich disaccharide obtained by a molecular rotation on its carrier linkage.\nThe alpha-anomeric Galbeta1-3GalNAc, called Thomsen-Friedenreich disaccharide (TFD), is overexpressed in epithelial cancer cells by aberrant O-glycosylation. TFD is also the main ligand of Agaricus bisporus lectin (ABL), a reversible noncytotoxic inhibitor of proliferation of epithelial cell lines. In order to obtain anti-TFD antibody response with a fine carbohydrate-binding specificity similar to that of ABL, we designed an immunogen of TFD with a molecular rotation on its carrier linkage that exposes more GalNAc than Gal, since ABL recognizes GalNAc more than Gal in TFD. The synthesis was accomplished by C-6 oxidation of Gal from TFD or its alpha-benzyl derivative (BzlalphaTFD), followed by reductive amination between the C-6 aldehyde yielded and the available amine of protein. Mice immunized with TFD-KLH (keyhole limpet hemocyanin) or BzlalphaTFD-KLH produced antibodies which were then analyzed by ELISA against several target antigens. Both immunogens raised anti-KLH antibody titers; however, TFD-KLH did not raise anti-TFD antibodies showing low TFD immunogenicity. In contrast, BzlalphaTFD-KLH gave much higher anti-TFD antibody response, indicating that benzyl residue helps improve anti-carbohydrate immune response. When IgG and IgM anti-TFD antibodies were analyzed by competitive ELISA using TFD-related carbohydrates as inhibitors, a high specificity to TFD as well as an enhanced binding to GalNAc over Gal were observed. The axial C-4 hydroxyl group of GalNAc interacted with IgG anti-TFD antibody, as evidenced by the lack of inhibitory activity of GlcNAc in contrast to GalNAc. These findings indicate that the anti-TFD antibodies have fine carbohydrate-binding specificity more similar to ABL than to other TFD-binding proteins that stimulate proliferation of epithelial cell lines."}

    EDAM-DFO

    {"project":"EDAM-DFO","denotations":[{"id":"T1","span":{"begin":533,"end":541},"obj":"http://edamontology.org/operation_2430"},{"id":"T2","span":{"begin":898,"end":905},"obj":"http://edamontology.org/format_1208"},{"id":"T3","span":{"begin":898,"end":905},"obj":"http://edamontology.org/data_1467"},{"id":"T4","span":{"begin":1298,"end":1305},"obj":"http://edamontology.org/data_1756"},{"id":"T5","span":{"begin":1445,"end":1461},"obj":"http://edamontology.org/data_2900"},{"id":"T6","span":{"begin":1646,"end":1655},"obj":"http://edamontology.org/data_2042"},{"id":"T7","span":{"begin":1866,"end":1874},"obj":"http://edamontology.org/data_1467"},{"id":"T8","span":{"begin":1866,"end":1874},"obj":"http://edamontology.org/format_1208"}],"text":"Novel immunogenicity of Thomsen-Friedenreich disaccharide obtained by a molecular rotation on its carrier linkage.\nThe alpha-anomeric Galbeta1-3GalNAc, called Thomsen-Friedenreich disaccharide (TFD), is overexpressed in epithelial cancer cells by aberrant O-glycosylation. TFD is also the main ligand of Agaricus bisporus lectin (ABL), a reversible noncytotoxic inhibitor of proliferation of epithelial cell lines. In order to obtain anti-TFD antibody response with a fine carbohydrate-binding specificity similar to that of ABL, we designed an immunogen of TFD with a molecular rotation on its carrier linkage that exposes more GalNAc than Gal, since ABL recognizes GalNAc more than Gal in TFD. The synthesis was accomplished by C-6 oxidation of Gal from TFD or its alpha-benzyl derivative (BzlalphaTFD), followed by reductive amination between the C-6 aldehyde yielded and the available amine of protein. Mice immunized with TFD-KLH (keyhole limpet hemocyanin) or BzlalphaTFD-KLH produced antibodies which were then analyzed by ELISA against several target antigens. Both immunogens raised anti-KLH antibody titers; however, TFD-KLH did not raise anti-TFD antibodies showing low TFD immunogenicity. In contrast, BzlalphaTFD-KLH gave much higher anti-TFD antibody response, indicating that benzyl residue helps improve anti-carbohydrate immune response. When IgG and IgM anti-TFD antibodies were analyzed by competitive ELISA using TFD-related carbohydrates as inhibitors, a high specificity to TFD as well as an enhanced binding to GalNAc over Gal were observed. The axial C-4 hydroxyl group of GalNAc interacted with IgG anti-TFD antibody, as evidenced by the lack of inhibitory activity of GlcNAc in contrast to GalNAc. These findings indicate that the anti-TFD antibodies have fine carbohydrate-binding specificity more similar to ABL than to other TFD-binding proteins that stimulate proliferation of epithelial cell lines."}

    NGLY1-deficiency

    {"project":"NGLY1-deficiency","denotations":[{"id":"PD-NGLY1-deficiency-B_T1","span":{"begin":1694,"end":1700},"obj":"chem:24139"}],"namespaces":[{"prefix":"hgnc","uri":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:"},{"prefix":"omim","uri":"https://www.omim.org/entry/"},{"prefix":"chem","uri":"https://pubchem.ncbi.nlm.nih.gov/compound/"}],"text":"Novel immunogenicity of Thomsen-Friedenreich disaccharide obtained by a molecular rotation on its carrier linkage.\nThe alpha-anomeric Galbeta1-3GalNAc, called Thomsen-Friedenreich disaccharide (TFD), is overexpressed in epithelial cancer cells by aberrant O-glycosylation. TFD is also the main ligand of Agaricus bisporus lectin (ABL), a reversible noncytotoxic inhibitor of proliferation of epithelial cell lines. In order to obtain anti-TFD antibody response with a fine carbohydrate-binding specificity similar to that of ABL, we designed an immunogen of TFD with a molecular rotation on its carrier linkage that exposes more GalNAc than Gal, since ABL recognizes GalNAc more than Gal in TFD. The synthesis was accomplished by C-6 oxidation of Gal from TFD or its alpha-benzyl derivative (BzlalphaTFD), followed by reductive amination between the C-6 aldehyde yielded and the available amine of protein. Mice immunized with TFD-KLH (keyhole limpet hemocyanin) or BzlalphaTFD-KLH produced antibodies which were then analyzed by ELISA against several target antigens. Both immunogens raised anti-KLH antibody titers; however, TFD-KLH did not raise anti-TFD antibodies showing low TFD immunogenicity. In contrast, BzlalphaTFD-KLH gave much higher anti-TFD antibody response, indicating that benzyl residue helps improve anti-carbohydrate immune response. When IgG and IgM anti-TFD antibodies were analyzed by competitive ELISA using TFD-related carbohydrates as inhibitors, a high specificity to TFD as well as an enhanced binding to GalNAc over Gal were observed. The axial C-4 hydroxyl group of GalNAc interacted with IgG anti-TFD antibody, as evidenced by the lack of inhibitory activity of GlcNAc in contrast to GalNAc. These findings indicate that the anti-TFD antibodies have fine carbohydrate-binding specificity more similar to ABL than to other TFD-binding proteins that stimulate proliferation of epithelial cell lines."}

    GlyTouCan-IUPAC

    {"project":"GlyTouCan-IUPAC","denotations":[{"id":"GlycanIUPAC_T1","span":{"begin":629,"end":635},"obj":"\"http://rdf.glycoinfo.org/glycan/G23425WZ\""},{"id":"GlycanIUPAC_T2","span":{"begin":667,"end":673},"obj":"\"http://rdf.glycoinfo.org/glycan/G23425WZ\""},{"id":"GlycanIUPAC_T3","span":{"begin":1534,"end":1540},"obj":"\"http://rdf.glycoinfo.org/glycan/G23425WZ\""},{"id":"GlycanIUPAC_T4","span":{"begin":1597,"end":1603},"obj":"\"http://rdf.glycoinfo.org/glycan/G23425WZ\""},{"id":"GlycanIUPAC_T5","span":{"begin":1716,"end":1722},"obj":"\"http://rdf.glycoinfo.org/glycan/G23425WZ\""},{"id":"GlycanIUPAC_T6","span":{"begin":629,"end":635},"obj":"\"http://rdf.glycoinfo.org/glycan/G02874VH\""},{"id":"GlycanIUPAC_T7","span":{"begin":667,"end":673},"obj":"\"http://rdf.glycoinfo.org/glycan/G02874VH\""},{"id":"GlycanIUPAC_T8","span":{"begin":1534,"end":1540},"obj":"\"http://rdf.glycoinfo.org/glycan/G02874VH\""},{"id":"GlycanIUPAC_T9","span":{"begin":1597,"end":1603},"obj":"\"http://rdf.glycoinfo.org/glycan/G02874VH\""},{"id":"GlycanIUPAC_T10","span":{"begin":1716,"end":1722},"obj":"\"http://rdf.glycoinfo.org/glycan/G02874VH\""},{"id":"GlycanIUPAC_T11","span":{"begin":629,"end":635},"obj":"\"http://rdf.glycoinfo.org/glycan/G99699DW\""},{"id":"GlycanIUPAC_T12","span":{"begin":667,"end":673},"obj":"\"http://rdf.glycoinfo.org/glycan/G99699DW\""},{"id":"GlycanIUPAC_T13","span":{"begin":1534,"end":1540},"obj":"\"http://rdf.glycoinfo.org/glycan/G99699DW\""},{"id":"GlycanIUPAC_T14","span":{"begin":1597,"end":1603},"obj":"\"http://rdf.glycoinfo.org/glycan/G99699DW\""},{"id":"GlycanIUPAC_T15","span":{"begin":1716,"end":1722},"obj":"\"http://rdf.glycoinfo.org/glycan/G99699DW\""},{"id":"GlycanIUPAC_T16","span":{"begin":629,"end":635},"obj":"\"http://rdf.glycoinfo.org/glycan/G22074RM\""},{"id":"GlycanIUPAC_T17","span":{"begin":667,"end":673},"obj":"\"http://rdf.glycoinfo.org/glycan/G22074RM\""},{"id":"GlycanIUPAC_T18","span":{"begin":1534,"end":1540},"obj":"\"http://rdf.glycoinfo.org/glycan/G22074RM\""},{"id":"GlycanIUPAC_T19","span":{"begin":1597,"end":1603},"obj":"\"http://rdf.glycoinfo.org/glycan/G22074RM\""},{"id":"GlycanIUPAC_T20","span":{"begin":1716,"end":1722},"obj":"\"http://rdf.glycoinfo.org/glycan/G22074RM\""},{"id":"GlycanIUPAC_T21","span":{"begin":629,"end":635},"obj":"\"http://rdf.glycoinfo.org/glycan/G48535VZ\""},{"id":"GlycanIUPAC_T22","span":{"begin":667,"end":673},"obj":"\"http://rdf.glycoinfo.org/glycan/G48535VZ\""},{"id":"GlycanIUPAC_T23","span":{"begin":1534,"end":1540},"obj":"\"http://rdf.glycoinfo.org/glycan/G48535VZ\""},{"id":"GlycanIUPAC_T24","span":{"begin":1597,"end":1603},"obj":"\"http://rdf.glycoinfo.org/glycan/G48535VZ\""},{"id":"GlycanIUPAC_T25","span":{"begin":1716,"end":1722},"obj":"\"http://rdf.glycoinfo.org/glycan/G48535VZ\""},{"id":"GlycanIUPAC_T26","span":{"begin":629,"end":635},"obj":"\"http://rdf.glycoinfo.org/glycan/G39738WL\""},{"id":"GlycanIUPAC_T27","span":{"begin":667,"end":673},"obj":"\"http://rdf.glycoinfo.org/glycan/G39738WL\""},{"id":"GlycanIUPAC_T28","span":{"begin":1534,"end":1540},"obj":"\"http://rdf.glycoinfo.org/glycan/G39738WL\""},{"id":"GlycanIUPAC_T29","span":{"begin":1597,"end":1603},"obj":"\"http://rdf.glycoinfo.org/glycan/G39738WL\""},{"id":"GlycanIUPAC_T30","span":{"begin":1716,"end":1722},"obj":"\"http://rdf.glycoinfo.org/glycan/G39738WL\""},{"id":"GlycanIUPAC_T31","span":{"begin":629,"end":635},"obj":"\"http://rdf.glycoinfo.org/glycan/G42313WU\""},{"id":"GlycanIUPAC_T32","span":{"begin":667,"end":673},"obj":"\"http://rdf.glycoinfo.org/glycan/G42313WU\""},{"id":"GlycanIUPAC_T33","span":{"begin":1534,"end":1540},"obj":"\"http://rdf.glycoinfo.org/glycan/G42313WU\""},{"id":"GlycanIUPAC_T34","span":{"begin":1597,"end":1603},"obj":"\"http://rdf.glycoinfo.org/glycan/G42313WU\""},{"id":"GlycanIUPAC_T35","span":{"begin":1716,"end":1722},"obj":"\"http://rdf.glycoinfo.org/glycan/G42313WU\""},{"id":"GlycanIUPAC_T36","span":{"begin":629,"end":635},"obj":"\"http://rdf.glycoinfo.org/glycan/G00393CK\""},{"id":"GlycanIUPAC_T37","span":{"begin":667,"end":673},"obj":"\"http://rdf.glycoinfo.org/glycan/G00393CK\""},{"id":"GlycanIUPAC_T38","span":{"begin":1534,"end":1540},"obj":"\"http://rdf.glycoinfo.org/glycan/G00393CK\""},{"id":"GlycanIUPAC_T39","span":{"begin":1597,"end":1603},"obj":"\"http://rdf.glycoinfo.org/glycan/G00393CK\""},{"id":"GlycanIUPAC_T40","span":{"begin":1716,"end":1722},"obj":"\"http://rdf.glycoinfo.org/glycan/G00393CK\""},{"id":"GlycanIUPAC_T41","span":{"begin":629,"end":635},"obj":"\"http://rdf.glycoinfo.org/glycan/G42649EX\""},{"id":"GlycanIUPAC_T42","span":{"begin":667,"end":673},"obj":"\"http://rdf.glycoinfo.org/glycan/G42649EX\""},{"id":"GlycanIUPAC_T43","span":{"begin":1534,"end":1540},"obj":"\"http://rdf.glycoinfo.org/glycan/G42649EX\""},{"id":"GlycanIUPAC_T44","span":{"begin":1597,"end":1603},"obj":"\"http://rdf.glycoinfo.org/glycan/G42649EX\""},{"id":"GlycanIUPAC_T45","span":{"begin":1716,"end":1722},"obj":"\"http://rdf.glycoinfo.org/glycan/G42649EX\""},{"id":"GlycanIUPAC_T46","span":{"begin":629,"end":635},"obj":"\"http://rdf.glycoinfo.org/glycan/G46880SB\""},{"id":"GlycanIUPAC_T47","span":{"begin":667,"end":673},"obj":"\"http://rdf.glycoinfo.org/glycan/G46880SB\""},{"id":"GlycanIUPAC_T48","span":{"begin":1534,"end":1540},"obj":"\"http://rdf.glycoinfo.org/glycan/G46880SB\""},{"id":"GlycanIUPAC_T49","span":{"begin":1597,"end":1603},"obj":"\"http://rdf.glycoinfo.org/glycan/G46880SB\""},{"id":"GlycanIUPAC_T50","span":{"begin":1716,"end":1722},"obj":"\"http://rdf.glycoinfo.org/glycan/G46880SB\""},{"id":"GlycanIUPAC_T51","span":{"begin":629,"end":635},"obj":"\"http://rdf.glycoinfo.org/glycan/G75599IR\""},{"id":"GlycanIUPAC_T52","span":{"begin":667,"end":673},"obj":"\"http://rdf.glycoinfo.org/glycan/G75599IR\""},{"id":"GlycanIUPAC_T53","span":{"begin":1534,"end":1540},"obj":"\"http://rdf.glycoinfo.org/glycan/G75599IR\""},{"id":"GlycanIUPAC_T54","span":{"begin":1597,"end":1603},"obj":"\"http://rdf.glycoinfo.org/glycan/G75599IR\""},{"id":"GlycanIUPAC_T55","span":{"begin":1716,"end":1722},"obj":"\"http://rdf.glycoinfo.org/glycan/G75599IR\""},{"id":"GlycanIUPAC_T56","span":{"begin":629,"end":635},"obj":"\"http://rdf.glycoinfo.org/glycan/G58985MU\""},{"id":"GlycanIUPAC_T57","span":{"begin":667,"end":673},"obj":"\"http://rdf.glycoinfo.org/glycan/G58985MU\""},{"id":"GlycanIUPAC_T58","span":{"begin":1534,"end":1540},"obj":"\"http://rdf.glycoinfo.org/glycan/G58985MU\""},{"id":"GlycanIUPAC_T59","span":{"begin":1597,"end":1603},"obj":"\"http://rdf.glycoinfo.org/glycan/G58985MU\""},{"id":"GlycanIUPAC_T60","span":{"begin":1716,"end":1722},"obj":"\"http://rdf.glycoinfo.org/glycan/G58985MU\""},{"id":"GlycanIUPAC_T61","span":{"begin":629,"end":635},"obj":"\"http://rdf.glycoinfo.org/glycan/G92517PO\""},{"id":"GlycanIUPAC_T62","span":{"begin":667,"end":673},"obj":"\"http://rdf.glycoinfo.org/glycan/G92517PO\""},{"id":"GlycanIUPAC_T63","span":{"begin":1534,"end":1540},"obj":"\"http://rdf.glycoinfo.org/glycan/G92517PO\""},{"id":"GlycanIUPAC_T64","span":{"begin":1597,"end":1603},"obj":"\"http://rdf.glycoinfo.org/glycan/G92517PO\""},{"id":"GlycanIUPAC_T65","span":{"begin":1716,"end":1722},"obj":"\"http://rdf.glycoinfo.org/glycan/G92517PO\""},{"id":"GlycanIUPAC_T66","span":{"begin":629,"end":635},"obj":"\"http://rdf.glycoinfo.org/glycan/G88512YL\""},{"id":"GlycanIUPAC_T67","span":{"begin":667,"end":673},"obj":"\"http://rdf.glycoinfo.org/glycan/G88512YL\""},{"id":"GlycanIUPAC_T68","span":{"begin":1534,"end":1540},"obj":"\"http://rdf.glycoinfo.org/glycan/G88512YL\""},{"id":"GlycanIUPAC_T69","span":{"begin":1597,"end":1603},"obj":"\"http://rdf.glycoinfo.org/glycan/G88512YL\""},{"id":"GlycanIUPAC_T70","span":{"begin":1716,"end":1722},"obj":"\"http://rdf.glycoinfo.org/glycan/G88512YL\""},{"id":"GlycanIUPAC_T71","span":{"begin":629,"end":635},"obj":"\"http://rdf.glycoinfo.org/glycan/G41473NX\""},{"id":"GlycanIUPAC_T72","span":{"begin":667,"end":673},"obj":"\"http://rdf.glycoinfo.org/glycan/G41473NX\""},{"id":"GlycanIUPAC_T73","span":{"begin":1534,"end":1540},"obj":"\"http://rdf.glycoinfo.org/glycan/G41473NX\""},{"id":"GlycanIUPAC_T74","span":{"begin":1597,"end":1603},"obj":"\"http://rdf.glycoinfo.org/glycan/G41473NX\""},{"id":"GlycanIUPAC_T75","span":{"begin":1716,"end":1722},"obj":"\"http://rdf.glycoinfo.org/glycan/G41473NX\""},{"id":"GlycanIUPAC_T76","span":{"begin":629,"end":635},"obj":"\"http://rdf.glycoinfo.org/glycan/G71089RB\""},{"id":"GlycanIUPAC_T77","span":{"begin":667,"end":673},"obj":"\"http://rdf.glycoinfo.org/glycan/G71089RB\""},{"id":"GlycanIUPAC_T78","span":{"begin":1534,"end":1540},"obj":"\"http://rdf.glycoinfo.org/glycan/G71089RB\""},{"id":"GlycanIUPAC_T79","span":{"begin":1597,"end":1603},"obj":"\"http://rdf.glycoinfo.org/glycan/G71089RB\""},{"id":"GlycanIUPAC_T80","span":{"begin":1716,"end":1722},"obj":"\"http://rdf.glycoinfo.org/glycan/G71089RB\""},{"id":"GlycanIUPAC_T81","span":{"begin":629,"end":635},"obj":"\"http://rdf.glycoinfo.org/glycan/G73485GZ\""},{"id":"GlycanIUPAC_T82","span":{"begin":667,"end":673},"obj":"\"http://rdf.glycoinfo.org/glycan/G73485GZ\""},{"id":"GlycanIUPAC_T83","span":{"begin":1534,"end":1540},"obj":"\"http://rdf.glycoinfo.org/glycan/G73485GZ\""},{"id":"GlycanIUPAC_T84","span":{"begin":1597,"end":1603},"obj":"\"http://rdf.glycoinfo.org/glycan/G73485GZ\""},{"id":"GlycanIUPAC_T85","span":{"begin":1716,"end":1722},"obj":"\"http://rdf.glycoinfo.org/glycan/G73485GZ\""},{"id":"GlycanIUPAC_T86","span":{"begin":629,"end":635},"obj":"\"http://rdf.glycoinfo.org/glycan/G61406KC\""},{"id":"GlycanIUPAC_T87","span":{"begin":667,"end":673},"obj":"\"http://rdf.glycoinfo.org/glycan/G61406KC\""},{"id":"GlycanIUPAC_T88","span":{"begin":1534,"end":1540},"obj":"\"http://rdf.glycoinfo.org/glycan/G61406KC\""},{"id":"GlycanIUPAC_T89","span":{"begin":1597,"end":1603},"obj":"\"http://rdf.glycoinfo.org/glycan/G61406KC\""},{"id":"GlycanIUPAC_T90","span":{"begin":1716,"end":1722},"obj":"\"http://rdf.glycoinfo.org/glycan/G61406KC\""},{"id":"GlycanIUPAC_T91","span":{"begin":629,"end":635},"obj":"\"http://rdf.glycoinfo.org/glycan/G34412GZ\""},{"id":"GlycanIUPAC_T92","span":{"begin":667,"end":673},"obj":"\"http://rdf.glycoinfo.org/glycan/G34412GZ\""},{"id":"GlycanIUPAC_T93","span":{"begin":1534,"end":1540},"obj":"\"http://rdf.glycoinfo.org/glycan/G34412GZ\""},{"id":"GlycanIUPAC_T94","span":{"begin":1597,"end":1603},"obj":"\"http://rdf.glycoinfo.org/glycan/G34412GZ\""},{"id":"GlycanIUPAC_T95","span":{"begin":1716,"end":1722},"obj":"\"http://rdf.glycoinfo.org/glycan/G34412GZ\""},{"id":"GlycanIUPAC_T96","span":{"begin":629,"end":635},"obj":"\"http://rdf.glycoinfo.org/glycan/G67209FP\""},{"id":"GlycanIUPAC_T97","span":{"begin":667,"end":673},"obj":"\"http://rdf.glycoinfo.org/glycan/G67209FP\""},{"id":"GlycanIUPAC_T98","span":{"begin":1534,"end":1540},"obj":"\"http://rdf.glycoinfo.org/glycan/G67209FP\""},{"id":"GlycanIUPAC_T99","span":{"begin":1597,"end":1603},"obj":"\"http://rdf.glycoinfo.org/glycan/G67209FP\""},{"id":"GlycanIUPAC_T100","span":{"begin":1716,"end":1722},"obj":"\"http://rdf.glycoinfo.org/glycan/G67209FP\""},{"id":"GlycanIUPAC_T101","span":{"begin":629,"end":635},"obj":"\"http://rdf.glycoinfo.org/glycan/G61442IL\""},{"id":"GlycanIUPAC_T102","span":{"begin":667,"end":673},"obj":"\"http://rdf.glycoinfo.org/glycan/G61442IL\""},{"id":"GlycanIUPAC_T103","span":{"begin":1534,"end":1540},"obj":"\"http://rdf.glycoinfo.org/glycan/G61442IL\""},{"id":"GlycanIUPAC_T104","span":{"begin":1597,"end":1603},"obj":"\"http://rdf.glycoinfo.org/glycan/G61442IL\""},{"id":"GlycanIUPAC_T105","span":{"begin":1716,"end":1722},"obj":"\"http://rdf.glycoinfo.org/glycan/G61442IL\""},{"id":"GlycanIUPAC_T106","span":{"begin":629,"end":635},"obj":"\"http://rdf.glycoinfo.org/glycan/G93729MV\""},{"id":"GlycanIUPAC_T107","span":{"begin":667,"end":673},"obj":"\"http://rdf.glycoinfo.org/glycan/G93729MV\""},{"id":"GlycanIUPAC_T108","span":{"begin":1534,"end":1540},"obj":"\"http://rdf.glycoinfo.org/glycan/G93729MV\""},{"id":"GlycanIUPAC_T109","span":{"begin":1597,"end":1603},"obj":"\"http://rdf.glycoinfo.org/glycan/G93729MV\""},{"id":"GlycanIUPAC_T110","span":{"begin":1716,"end":1722},"obj":"\"http://rdf.glycoinfo.org/glycan/G93729MV\""},{"id":"GlycanIUPAC_T111","span":{"begin":629,"end":635},"obj":"\"http://rdf.glycoinfo.org/glycan/G92144AE\""},{"id":"GlycanIUPAC_T112","span":{"begin":667,"end":673},"obj":"\"http://rdf.glycoinfo.org/glycan/G92144AE\""},{"id":"GlycanIUPAC_T113","span":{"begin":1534,"end":1540},"obj":"\"http://rdf.glycoinfo.org/glycan/G92144AE\""},{"id":"GlycanIUPAC_T114","span":{"begin":1597,"end":1603},"obj":"\"http://rdf.glycoinfo.org/glycan/G92144AE\""},{"id":"GlycanIUPAC_T115","span":{"begin":1716,"end":1722},"obj":"\"http://rdf.glycoinfo.org/glycan/G92144AE\""},{"id":"GlycanIUPAC_T116","span":{"begin":641,"end":644},"obj":"\"http://rdf.glycoinfo.org/glycan/G93924TT\""},{"id":"GlycanIUPAC_T117","span":{"begin":684,"end":687},"obj":"\"http://rdf.glycoinfo.org/glycan/G93924TT\""},{"id":"GlycanIUPAC_T118","span":{"begin":747,"end":750},"obj":"\"http://rdf.glycoinfo.org/glycan/G93924TT\""},{"id":"GlycanIUPAC_T119","span":{"begin":1546,"end":1549},"obj":"\"http://rdf.glycoinfo.org/glycan/G93924TT\""},{"id":"GlycanIUPAC_T120","span":{"begin":641,"end":644},"obj":"\"http://rdf.glycoinfo.org/glycan/G25565DN\""},{"id":"GlycanIUPAC_T121","span":{"begin":684,"end":687},"obj":"\"http://rdf.glycoinfo.org/glycan/G25565DN\""},{"id":"GlycanIUPAC_T122","span":{"begin":747,"end":750},"obj":"\"http://rdf.glycoinfo.org/glycan/G25565DN\""},{"id":"GlycanIUPAC_T123","span":{"begin":1546,"end":1549},"obj":"\"http://rdf.glycoinfo.org/glycan/G25565DN\""},{"id":"GlycanIUPAC_T124","span":{"begin":641,"end":644},"obj":"\"http://rdf.glycoinfo.org/glycan/G97215EV\""},{"id":"GlycanIUPAC_T125","span":{"begin":684,"end":687},"obj":"\"http://rdf.glycoinfo.org/glycan/G97215EV\""},{"id":"GlycanIUPAC_T126","span":{"begin":747,"end":750},"obj":"\"http://rdf.glycoinfo.org/glycan/G97215EV\""},{"id":"GlycanIUPAC_T127","span":{"begin":1546,"end":1549},"obj":"\"http://rdf.glycoinfo.org/glycan/G97215EV\""},{"id":"GlycanIUPAC_T128","span":{"begin":641,"end":644},"obj":"\"http://rdf.glycoinfo.org/glycan/G79664KO\""},{"id":"GlycanIUPAC_T129","span":{"begin":684,"end":687},"obj":"\"http://rdf.glycoinfo.org/glycan/G79664KO\""},{"id":"GlycanIUPAC_T130","span":{"begin":747,"end":750},"obj":"\"http://rdf.glycoinfo.org/glycan/G79664KO\""},{"id":"GlycanIUPAC_T131","span":{"begin":1546,"end":1549},"obj":"\"http://rdf.glycoinfo.org/glycan/G79664KO\""},{"id":"GlycanIUPAC_T132","span":{"begin":641,"end":644},"obj":"\"http://rdf.glycoinfo.org/glycan/G24107FU\""},{"id":"GlycanIUPAC_T133","span":{"begin":684,"end":687},"obj":"\"http://rdf.glycoinfo.org/glycan/G24107FU\""},{"id":"GlycanIUPAC_T134","span":{"begin":747,"end":750},"obj":"\"http://rdf.glycoinfo.org/glycan/G24107FU\""},{"id":"GlycanIUPAC_T135","span":{"begin":1546,"end":1549},"obj":"\"http://rdf.glycoinfo.org/glycan/G24107FU\""},{"id":"GlycanIUPAC_T136","span":{"begin":641,"end":644},"obj":"\"http://rdf.glycoinfo.org/glycan/G09864UE\""},{"id":"GlycanIUPAC_T137","span":{"begin":684,"end":687},"obj":"\"http://rdf.glycoinfo.org/glycan/G09864UE\""},{"id":"GlycanIUPAC_T138","span":{"begin":747,"end":750},"obj":"\"http://rdf.glycoinfo.org/glycan/G09864UE\""},{"id":"GlycanIUPAC_T139","span":{"begin":1546,"end":1549},"obj":"\"http://rdf.glycoinfo.org/glycan/G09864UE\""},{"id":"GlycanIUPAC_T140","span":{"begin":641,"end":644},"obj":"\"http://rdf.glycoinfo.org/glycan/G28032MC\""},{"id":"GlycanIUPAC_T141","span":{"begin":684,"end":687},"obj":"\"http://rdf.glycoinfo.org/glycan/G28032MC\""},{"id":"GlycanIUPAC_T142","span":{"begin":747,"end":750},"obj":"\"http://rdf.glycoinfo.org/glycan/G28032MC\""},{"id":"GlycanIUPAC_T143","span":{"begin":1546,"end":1549},"obj":"\"http://rdf.glycoinfo.org/glycan/G28032MC\""},{"id":"GlycanIUPAC_T144","span":{"begin":641,"end":644},"obj":"\"http://rdf.glycoinfo.org/glycan/G28005UP\""},{"id":"GlycanIUPAC_T145","span":{"begin":684,"end":687},"obj":"\"http://rdf.glycoinfo.org/glycan/G28005UP\""},{"id":"GlycanIUPAC_T146","span":{"begin":747,"end":750},"obj":"\"http://rdf.glycoinfo.org/glycan/G28005UP\""},{"id":"GlycanIUPAC_T147","span":{"begin":1546,"end":1549},"obj":"\"http://rdf.glycoinfo.org/glycan/G28005UP\""},{"id":"GlycanIUPAC_T148","span":{"begin":641,"end":644},"obj":"\"http://rdf.glycoinfo.org/glycan/G92708AT\""},{"id":"GlycanIUPAC_T149","span":{"begin":684,"end":687},"obj":"\"http://rdf.glycoinfo.org/glycan/G92708AT\""},{"id":"GlycanIUPAC_T150","span":{"begin":747,"end":750},"obj":"\"http://rdf.glycoinfo.org/glycan/G92708AT\""},{"id":"GlycanIUPAC_T151","span":{"begin":1546,"end":1549},"obj":"\"http://rdf.glycoinfo.org/glycan/G92708AT\""},{"id":"GlycanIUPAC_T152","span":{"begin":641,"end":644},"obj":"\"http://rdf.glycoinfo.org/glycan/G73757UC\""},{"id":"GlycanIUPAC_T153","span":{"begin":684,"end":687},"obj":"\"http://rdf.glycoinfo.org/glycan/G73757UC\""},{"id":"GlycanIUPAC_T154","span":{"begin":747,"end":750},"obj":"\"http://rdf.glycoinfo.org/glycan/G73757UC\""},{"id":"GlycanIUPAC_T155","span":{"begin":1546,"end":1549},"obj":"\"http://rdf.glycoinfo.org/glycan/G73757UC\""},{"id":"GlycanIUPAC_T156","span":{"begin":641,"end":644},"obj":"\"http://rdf.glycoinfo.org/glycan/G51062DM\""},{"id":"GlycanIUPAC_T157","span":{"begin":684,"end":687},"obj":"\"http://rdf.glycoinfo.org/glycan/G51062DM\""},{"id":"GlycanIUPAC_T158","span":{"begin":747,"end":750},"obj":"\"http://rdf.glycoinfo.org/glycan/G51062DM\""},{"id":"GlycanIUPAC_T159","span":{"begin":1546,"end":1549},"obj":"\"http://rdf.glycoinfo.org/glycan/G51062DM\""},{"id":"GlycanIUPAC_T160","span":{"begin":641,"end":644},"obj":"\"http://rdf.glycoinfo.org/glycan/G05866BJ\""},{"id":"GlycanIUPAC_T161","span":{"begin":684,"end":687},"obj":"\"http://rdf.glycoinfo.org/glycan/G05866BJ\""},{"id":"GlycanIUPAC_T162","span":{"begin":747,"end":750},"obj":"\"http://rdf.glycoinfo.org/glycan/G05866BJ\""},{"id":"GlycanIUPAC_T163","span":{"begin":1546,"end":1549},"obj":"\"http://rdf.glycoinfo.org/glycan/G05866BJ\""},{"id":"GlycanIUPAC_T164","span":{"begin":641,"end":644},"obj":"\"http://rdf.glycoinfo.org/glycan/G87394FZ\""},{"id":"GlycanIUPAC_T165","span":{"begin":684,"end":687},"obj":"\"http://rdf.glycoinfo.org/glycan/G87394FZ\""},{"id":"GlycanIUPAC_T166","span":{"begin":747,"end":750},"obj":"\"http://rdf.glycoinfo.org/glycan/G87394FZ\""},{"id":"GlycanIUPAC_T167","span":{"begin":1546,"end":1549},"obj":"\"http://rdf.glycoinfo.org/glycan/G87394FZ\""},{"id":"GlycanIUPAC_T168","span":{"begin":641,"end":644},"obj":"\"http://rdf.glycoinfo.org/glycan/G03871NF\""},{"id":"GlycanIUPAC_T169","span":{"begin":684,"end":687},"obj":"\"http://rdf.glycoinfo.org/glycan/G03871NF\""},{"id":"GlycanIUPAC_T170","span":{"begin":747,"end":750},"obj":"\"http://rdf.glycoinfo.org/glycan/G03871NF\""},{"id":"GlycanIUPAC_T171","span":{"begin":1546,"end":1549},"obj":"\"http://rdf.glycoinfo.org/glycan/G03871NF\""},{"id":"GlycanIUPAC_T172","span":{"begin":641,"end":644},"obj":"\"http://rdf.glycoinfo.org/glycan/G29377VE\""},{"id":"GlycanIUPAC_T173","span":{"begin":684,"end":687},"obj":"\"http://rdf.glycoinfo.org/glycan/G29377VE\""},{"id":"GlycanIUPAC_T174","span":{"begin":747,"end":750},"obj":"\"http://rdf.glycoinfo.org/glycan/G29377VE\""},{"id":"GlycanIUPAC_T175","span":{"begin":1546,"end":1549},"obj":"\"http://rdf.glycoinfo.org/glycan/G29377VE\""},{"id":"GlycanIUPAC_T176","span":{"begin":641,"end":644},"obj":"\"http://rdf.glycoinfo.org/glycan/G33457CX\""},{"id":"GlycanIUPAC_T177","span":{"begin":684,"end":687},"obj":"\"http://rdf.glycoinfo.org/glycan/G33457CX\""},{"id":"GlycanIUPAC_T178","span":{"begin":747,"end":750},"obj":"\"http://rdf.glycoinfo.org/glycan/G33457CX\""},{"id":"GlycanIUPAC_T179","span":{"begin":1546,"end":1549},"obj":"\"http://rdf.glycoinfo.org/glycan/G33457CX\""},{"id":"GlycanIUPAC_T180","span":{"begin":641,"end":644},"obj":"\"http://rdf.glycoinfo.org/glycan/G97368GU\""},{"id":"GlycanIUPAC_T181","span":{"begin":684,"end":687},"obj":"\"http://rdf.glycoinfo.org/glycan/G97368GU\""},{"id":"GlycanIUPAC_T182","span":{"begin":747,"end":750},"obj":"\"http://rdf.glycoinfo.org/glycan/G97368GU\""},{"id":"GlycanIUPAC_T183","span":{"begin":1546,"end":1549},"obj":"\"http://rdf.glycoinfo.org/glycan/G97368GU\""},{"id":"GlycanIUPAC_T184","span":{"begin":641,"end":644},"obj":"\"http://rdf.glycoinfo.org/glycan/G18512EL\""},{"id":"GlycanIUPAC_T185","span":{"begin":684,"end":687},"obj":"\"http://rdf.glycoinfo.org/glycan/G18512EL\""},{"id":"GlycanIUPAC_T186","span":{"begin":747,"end":750},"obj":"\"http://rdf.glycoinfo.org/glycan/G18512EL\""},{"id":"GlycanIUPAC_T187","span":{"begin":1546,"end":1549},"obj":"\"http://rdf.glycoinfo.org/glycan/G18512EL\""},{"id":"GlycanIUPAC_T188","span":{"begin":641,"end":644},"obj":"\"http://rdf.glycoinfo.org/glycan/G41137VS\""},{"id":"GlycanIUPAC_T189","span":{"begin":684,"end":687},"obj":"\"http://rdf.glycoinfo.org/glycan/G41137VS\""},{"id":"GlycanIUPAC_T190","span":{"begin":747,"end":750},"obj":"\"http://rdf.glycoinfo.org/glycan/G41137VS\""},{"id":"GlycanIUPAC_T191","span":{"begin":1546,"end":1549},"obj":"\"http://rdf.glycoinfo.org/glycan/G41137VS\""},{"id":"GlycanIUPAC_T192","span":{"begin":641,"end":644},"obj":"\"http://rdf.glycoinfo.org/glycan/G30521NA\""},{"id":"GlycanIUPAC_T193","span":{"begin":684,"end":687},"obj":"\"http://rdf.glycoinfo.org/glycan/G30521NA\""},{"id":"GlycanIUPAC_T194","span":{"begin":747,"end":750},"obj":"\"http://rdf.glycoinfo.org/glycan/G30521NA\""},{"id":"GlycanIUPAC_T195","span":{"begin":1546,"end":1549},"obj":"\"http://rdf.glycoinfo.org/glycan/G30521NA\""},{"id":"GlycanIUPAC_T196","span":{"begin":641,"end":644},"obj":"\"http://rdf.glycoinfo.org/glycan/G19388CD\""},{"id":"GlycanIUPAC_T197","span":{"begin":684,"end":687},"obj":"\"http://rdf.glycoinfo.org/glycan/G19388CD\""},{"id":"GlycanIUPAC_T198","span":{"begin":747,"end":750},"obj":"\"http://rdf.glycoinfo.org/glycan/G19388CD\""},{"id":"GlycanIUPAC_T199","span":{"begin":1546,"end":1549},"obj":"\"http://rdf.glycoinfo.org/glycan/G19388CD\""},{"id":"GlycanIUPAC_T200","span":{"begin":641,"end":644},"obj":"\"http://rdf.glycoinfo.org/glycan/G53151FU\""},{"id":"GlycanIUPAC_T201","span":{"begin":684,"end":687},"obj":"\"http://rdf.glycoinfo.org/glycan/G53151FU\""},{"id":"GlycanIUPAC_T202","span":{"begin":747,"end":750},"obj":"\"http://rdf.glycoinfo.org/glycan/G53151FU\""},{"id":"GlycanIUPAC_T203","span":{"begin":1546,"end":1549},"obj":"\"http://rdf.glycoinfo.org/glycan/G53151FU\""},{"id":"GlycanIUPAC_T204","span":{"begin":641,"end":644},"obj":"\"http://rdf.glycoinfo.org/glycan/G27105XC\""},{"id":"GlycanIUPAC_T205","span":{"begin":684,"end":687},"obj":"\"http://rdf.glycoinfo.org/glycan/G27105XC\""},{"id":"GlycanIUPAC_T206","span":{"begin":747,"end":750},"obj":"\"http://rdf.glycoinfo.org/glycan/G27105XC\""},{"id":"GlycanIUPAC_T207","span":{"begin":1546,"end":1549},"obj":"\"http://rdf.glycoinfo.org/glycan/G27105XC\""},{"id":"GlycanIUPAC_T208","span":{"begin":641,"end":644},"obj":"\"http://rdf.glycoinfo.org/glycan/G91210VM\""},{"id":"GlycanIUPAC_T209","span":{"begin":684,"end":687},"obj":"\"http://rdf.glycoinfo.org/glycan/G91210VM\""},{"id":"GlycanIUPAC_T210","span":{"begin":747,"end":750},"obj":"\"http://rdf.glycoinfo.org/glycan/G91210VM\""},{"id":"GlycanIUPAC_T211","span":{"begin":1546,"end":1549},"obj":"\"http://rdf.glycoinfo.org/glycan/G91210VM\""},{"id":"GlycanIUPAC_T212","span":{"begin":641,"end":644},"obj":"\"http://rdf.glycoinfo.org/glycan/G40841DE\""},{"id":"GlycanIUPAC_T213","span":{"begin":684,"end":687},"obj":"\"http://rdf.glycoinfo.org/glycan/G40841DE\""},{"id":"GlycanIUPAC_T214","span":{"begin":747,"end":750},"obj":"\"http://rdf.glycoinfo.org/glycan/G40841DE\""},{"id":"GlycanIUPAC_T215","span":{"begin":1546,"end":1549},"obj":"\"http://rdf.glycoinfo.org/glycan/G40841DE\""},{"id":"GlycanIUPAC_T216","span":{"begin":641,"end":644},"obj":"\"http://rdf.glycoinfo.org/glycan/G71241HP\""},{"id":"GlycanIUPAC_T217","span":{"begin":684,"end":687},"obj":"\"http://rdf.glycoinfo.org/glycan/G71241HP\""},{"id":"GlycanIUPAC_T218","span":{"begin":747,"end":750},"obj":"\"http://rdf.glycoinfo.org/glycan/G71241HP\""},{"id":"GlycanIUPAC_T219","span":{"begin":1546,"end":1549},"obj":"\"http://rdf.glycoinfo.org/glycan/G71241HP\""},{"id":"GlycanIUPAC_T220","span":{"begin":641,"end":644},"obj":"\"http://rdf.glycoinfo.org/glycan/G84636BJ\""},{"id":"GlycanIUPAC_T221","span":{"begin":684,"end":687},"obj":"\"http://rdf.glycoinfo.org/glycan/G84636BJ\""},{"id":"GlycanIUPAC_T222","span":{"begin":747,"end":750},"obj":"\"http://rdf.glycoinfo.org/glycan/G84636BJ\""},{"id":"GlycanIUPAC_T223","span":{"begin":1546,"end":1549},"obj":"\"http://rdf.glycoinfo.org/glycan/G84636BJ\""},{"id":"GlycanIUPAC_T224","span":{"begin":641,"end":644},"obj":"\"http://rdf.glycoinfo.org/glycan/G47905LJ\""},{"id":"GlycanIUPAC_T225","span":{"begin":684,"end":687},"obj":"\"http://rdf.glycoinfo.org/glycan/G47905LJ\""},{"id":"GlycanIUPAC_T226","span":{"begin":747,"end":750},"obj":"\"http://rdf.glycoinfo.org/glycan/G47905LJ\""},{"id":"GlycanIUPAC_T227","span":{"begin":1546,"end":1549},"obj":"\"http://rdf.glycoinfo.org/glycan/G47905LJ\""},{"id":"GlycanIUPAC_T228","span":{"begin":641,"end":644},"obj":"\"http://rdf.glycoinfo.org/glycan/G39340DV\""},{"id":"GlycanIUPAC_T229","span":{"begin":684,"end":687},"obj":"\"http://rdf.glycoinfo.org/glycan/G39340DV\""},{"id":"GlycanIUPAC_T230","span":{"begin":747,"end":750},"obj":"\"http://rdf.glycoinfo.org/glycan/G39340DV\""},{"id":"GlycanIUPAC_T231","span":{"begin":1546,"end":1549},"obj":"\"http://rdf.glycoinfo.org/glycan/G39340DV\""},{"id":"GlycanIUPAC_T232","span":{"begin":641,"end":644},"obj":"\"http://rdf.glycoinfo.org/glycan/G48801AQ\""},{"id":"GlycanIUPAC_T233","span":{"begin":684,"end":687},"obj":"\"http://rdf.glycoinfo.org/glycan/G48801AQ\""},{"id":"GlycanIUPAC_T234","span":{"begin":747,"end":750},"obj":"\"http://rdf.glycoinfo.org/glycan/G48801AQ\""},{"id":"GlycanIUPAC_T235","span":{"begin":1546,"end":1549},"obj":"\"http://rdf.glycoinfo.org/glycan/G48801AQ\""},{"id":"GlycanIUPAC_T236","span":{"begin":641,"end":644},"obj":"\"http://rdf.glycoinfo.org/glycan/G14573NX\""},{"id":"GlycanIUPAC_T237","span":{"begin":684,"end":687},"obj":"\"http://rdf.glycoinfo.org/glycan/G14573NX\""},{"id":"GlycanIUPAC_T238","span":{"begin":747,"end":750},"obj":"\"http://rdf.glycoinfo.org/glycan/G14573NX\""},{"id":"GlycanIUPAC_T239","span":{"begin":1546,"end":1549},"obj":"\"http://rdf.glycoinfo.org/glycan/G14573NX\""},{"id":"GlycanIUPAC_T240","span":{"begin":641,"end":644},"obj":"\"http://rdf.glycoinfo.org/glycan/G56762TR\""},{"id":"GlycanIUPAC_T241","span":{"begin":684,"end":687},"obj":"\"http://rdf.glycoinfo.org/glycan/G56762TR\""},{"id":"GlycanIUPAC_T242","span":{"begin":747,"end":750},"obj":"\"http://rdf.glycoinfo.org/glycan/G56762TR\""},{"id":"GlycanIUPAC_T243","span":{"begin":1546,"end":1549},"obj":"\"http://rdf.glycoinfo.org/glycan/G56762TR\""},{"id":"GlycanIUPAC_T244","span":{"begin":641,"end":644},"obj":"\"http://rdf.glycoinfo.org/glycan/G20013XO\""},{"id":"GlycanIUPAC_T245","span":{"begin":684,"end":687},"obj":"\"http://rdf.glycoinfo.org/glycan/G20013XO\""},{"id":"GlycanIUPAC_T246","span":{"begin":747,"end":750},"obj":"\"http://rdf.glycoinfo.org/glycan/G20013XO\""},{"id":"GlycanIUPAC_T247","span":{"begin":1546,"end":1549},"obj":"\"http://rdf.glycoinfo.org/glycan/G20013XO\""},{"id":"GlycanIUPAC_T248","span":{"begin":641,"end":644},"obj":"\"http://rdf.glycoinfo.org/glycan/G39504DR\""},{"id":"GlycanIUPAC_T249","span":{"begin":684,"end":687},"obj":"\"http://rdf.glycoinfo.org/glycan/G39504DR\""},{"id":"GlycanIUPAC_T250","span":{"begin":747,"end":750},"obj":"\"http://rdf.glycoinfo.org/glycan/G39504DR\""},{"id":"GlycanIUPAC_T251","span":{"begin":1546,"end":1549},"obj":"\"http://rdf.glycoinfo.org/glycan/G39504DR\""},{"id":"GlycanIUPAC_T252","span":{"begin":641,"end":644},"obj":"\"http://rdf.glycoinfo.org/glycan/G35218RQ\""},{"id":"GlycanIUPAC_T253","span":{"begin":684,"end":687},"obj":"\"http://rdf.glycoinfo.org/glycan/G35218RQ\""},{"id":"GlycanIUPAC_T254","span":{"begin":747,"end":750},"obj":"\"http://rdf.glycoinfo.org/glycan/G35218RQ\""},{"id":"GlycanIUPAC_T255","span":{"begin":1546,"end":1549},"obj":"\"http://rdf.glycoinfo.org/glycan/G35218RQ\""},{"id":"GlycanIUPAC_T256","span":{"begin":641,"end":644},"obj":"\"http://rdf.glycoinfo.org/glycan/G53048SH\""},{"id":"GlycanIUPAC_T257","span":{"begin":684,"end":687},"obj":"\"http://rdf.glycoinfo.org/glycan/G53048SH\""},{"id":"GlycanIUPAC_T258","span":{"begin":747,"end":750},"obj":"\"http://rdf.glycoinfo.org/glycan/G53048SH\""},{"id":"GlycanIUPAC_T259","span":{"begin":1546,"end":1549},"obj":"\"http://rdf.glycoinfo.org/glycan/G53048SH\""},{"id":"GlycanIUPAC_T260","span":{"begin":641,"end":644},"obj":"\"http://rdf.glycoinfo.org/glycan/G78418IX\""},{"id":"GlycanIUPAC_T261","span":{"begin":684,"end":687},"obj":"\"http://rdf.glycoinfo.org/glycan/G78418IX\""},{"id":"GlycanIUPAC_T262","span":{"begin":747,"end":750},"obj":"\"http://rdf.glycoinfo.org/glycan/G78418IX\""},{"id":"GlycanIUPAC_T263","span":{"begin":1546,"end":1549},"obj":"\"http://rdf.glycoinfo.org/glycan/G78418IX\""},{"id":"GlycanIUPAC_T264","span":{"begin":641,"end":644},"obj":"\"http://rdf.glycoinfo.org/glycan/G09780OD\""},{"id":"GlycanIUPAC_T265","span":{"begin":684,"end":687},"obj":"\"http://rdf.glycoinfo.org/glycan/G09780OD\""},{"id":"GlycanIUPAC_T266","span":{"begin":747,"end":750},"obj":"\"http://rdf.glycoinfo.org/glycan/G09780OD\""},{"id":"GlycanIUPAC_T267","span":{"begin":1546,"end":1549},"obj":"\"http://rdf.glycoinfo.org/glycan/G09780OD\""},{"id":"GlycanIUPAC_T268","span":{"begin":641,"end":644},"obj":"\"http://rdf.glycoinfo.org/glycan/G56359GL\""},{"id":"GlycanIUPAC_T269","span":{"begin":684,"end":687},"obj":"\"http://rdf.glycoinfo.org/glycan/G56359GL\""},{"id":"GlycanIUPAC_T270","span":{"begin":747,"end":750},"obj":"\"http://rdf.glycoinfo.org/glycan/G56359GL\""},{"id":"GlycanIUPAC_T271","span":{"begin":1546,"end":1549},"obj":"\"http://rdf.glycoinfo.org/glycan/G56359GL\""},{"id":"GlycanIUPAC_T272","span":{"begin":641,"end":644},"obj":"\"http://rdf.glycoinfo.org/glycan/G78941YC\""},{"id":"GlycanIUPAC_T273","span":{"begin":684,"end":687},"obj":"\"http://rdf.glycoinfo.org/glycan/G78941YC\""},{"id":"GlycanIUPAC_T274","span":{"begin":747,"end":750},"obj":"\"http://rdf.glycoinfo.org/glycan/G78941YC\""},{"id":"GlycanIUPAC_T275","span":{"begin":1546,"end":1549},"obj":"\"http://rdf.glycoinfo.org/glycan/G78941YC\""},{"id":"GlycanIUPAC_T276","span":{"begin":641,"end":644},"obj":"\"http://rdf.glycoinfo.org/glycan/G26829FC\""},{"id":"GlycanIUPAC_T277","span":{"begin":684,"end":687},"obj":"\"http://rdf.glycoinfo.org/glycan/G26829FC\""},{"id":"GlycanIUPAC_T278","span":{"begin":747,"end":750},"obj":"\"http://rdf.glycoinfo.org/glycan/G26829FC\""},{"id":"GlycanIUPAC_T279","span":{"begin":1546,"end":1549},"obj":"\"http://rdf.glycoinfo.org/glycan/G26829FC\""},{"id":"GlycanIUPAC_T280","span":{"begin":641,"end":644},"obj":"\"http://rdf.glycoinfo.org/glycan/G88538ZC\""},{"id":"GlycanIUPAC_T281","span":{"begin":684,"end":687},"obj":"\"http://rdf.glycoinfo.org/glycan/G88538ZC\""},{"id":"GlycanIUPAC_T282","span":{"begin":747,"end":750},"obj":"\"http://rdf.glycoinfo.org/glycan/G88538ZC\""},{"id":"GlycanIUPAC_T283","span":{"begin":1546,"end":1549},"obj":"\"http://rdf.glycoinfo.org/glycan/G88538ZC\""},{"id":"GlycanIUPAC_T284","span":{"begin":641,"end":644},"obj":"\"http://rdf.glycoinfo.org/glycan/G46593ZR\""},{"id":"GlycanIUPAC_T285","span":{"begin":684,"end":687},"obj":"\"http://rdf.glycoinfo.org/glycan/G46593ZR\""},{"id":"GlycanIUPAC_T286","span":{"begin":747,"end":750},"obj":"\"http://rdf.glycoinfo.org/glycan/G46593ZR\""},{"id":"GlycanIUPAC_T287","span":{"begin":1546,"end":1549},"obj":"\"http://rdf.glycoinfo.org/glycan/G46593ZR\""},{"id":"GlycanIUPAC_T288","span":{"begin":641,"end":644},"obj":"\"http://rdf.glycoinfo.org/glycan/G43523TH\""},{"id":"GlycanIUPAC_T289","span":{"begin":684,"end":687},"obj":"\"http://rdf.glycoinfo.org/glycan/G43523TH\""},{"id":"GlycanIUPAC_T290","span":{"begin":747,"end":750},"obj":"\"http://rdf.glycoinfo.org/glycan/G43523TH\""},{"id":"GlycanIUPAC_T291","span":{"begin":1546,"end":1549},"obj":"\"http://rdf.glycoinfo.org/glycan/G43523TH\""},{"id":"GlycanIUPAC_T292","span":{"begin":641,"end":644},"obj":"\"http://rdf.glycoinfo.org/glycan/G36445ON\""},{"id":"GlycanIUPAC_T293","span":{"begin":684,"end":687},"obj":"\"http://rdf.glycoinfo.org/glycan/G36445ON\""},{"id":"GlycanIUPAC_T294","span":{"begin":747,"end":750},"obj":"\"http://rdf.glycoinfo.org/glycan/G36445ON\""},{"id":"GlycanIUPAC_T295","span":{"begin":1546,"end":1549},"obj":"\"http://rdf.glycoinfo.org/glycan/G36445ON\""},{"id":"GlycanIUPAC_T296","span":{"begin":641,"end":644},"obj":"\"http://rdf.glycoinfo.org/glycan/G67363FK\""},{"id":"GlycanIUPAC_T297","span":{"begin":684,"end":687},"obj":"\"http://rdf.glycoinfo.org/glycan/G67363FK\""},{"id":"GlycanIUPAC_T298","span":{"begin":747,"end":750},"obj":"\"http://rdf.glycoinfo.org/glycan/G67363FK\""},{"id":"GlycanIUPAC_T299","span":{"begin":1546,"end":1549},"obj":"\"http://rdf.glycoinfo.org/glycan/G67363FK\""},{"id":"GlycanIUPAC_T300","span":{"begin":641,"end":644},"obj":"\"http://rdf.glycoinfo.org/glycan/G17562KT\""},{"id":"GlycanIUPAC_T301","span":{"begin":684,"end":687},"obj":"\"http://rdf.glycoinfo.org/glycan/G17562KT\""},{"id":"GlycanIUPAC_T302","span":{"begin":747,"end":750},"obj":"\"http://rdf.glycoinfo.org/glycan/G17562KT\""},{"id":"GlycanIUPAC_T303","span":{"begin":1546,"end":1549},"obj":"\"http://rdf.glycoinfo.org/glycan/G17562KT\""},{"id":"GlycanIUPAC_T304","span":{"begin":641,"end":644},"obj":"\"http://rdf.glycoinfo.org/glycan/G24774YJ\""},{"id":"GlycanIUPAC_T305","span":{"begin":684,"end":687},"obj":"\"http://rdf.glycoinfo.org/glycan/G24774YJ\""},{"id":"GlycanIUPAC_T306","span":{"begin":747,"end":750},"obj":"\"http://rdf.glycoinfo.org/glycan/G24774YJ\""},{"id":"GlycanIUPAC_T307","span":{"begin":1546,"end":1549},"obj":"\"http://rdf.glycoinfo.org/glycan/G24774YJ\""},{"id":"GlycanIUPAC_T308","span":{"begin":641,"end":644},"obj":"\"http://rdf.glycoinfo.org/glycan/G32162UO\""},{"id":"GlycanIUPAC_T309","span":{"begin":684,"end":687},"obj":"\"http://rdf.glycoinfo.org/glycan/G32162UO\""},{"id":"GlycanIUPAC_T310","span":{"begin":747,"end":750},"obj":"\"http://rdf.glycoinfo.org/glycan/G32162UO\""},{"id":"GlycanIUPAC_T311","span":{"begin":1546,"end":1549},"obj":"\"http://rdf.glycoinfo.org/glycan/G32162UO\""},{"id":"GlycanIUPAC_T312","span":{"begin":641,"end":644},"obj":"\"http://rdf.glycoinfo.org/glycan/G89163RR\""},{"id":"GlycanIUPAC_T313","span":{"begin":684,"end":687},"obj":"\"http://rdf.glycoinfo.org/glycan/G89163RR\""},{"id":"GlycanIUPAC_T314","span":{"begin":747,"end":750},"obj":"\"http://rdf.glycoinfo.org/glycan/G89163RR\""},{"id":"GlycanIUPAC_T315","span":{"begin":1546,"end":1549},"obj":"\"http://rdf.glycoinfo.org/glycan/G89163RR\""},{"id":"GlycanIUPAC_T316","span":{"begin":641,"end":644},"obj":"\"http://rdf.glycoinfo.org/glycan/G99522DY\""},{"id":"GlycanIUPAC_T317","span":{"begin":684,"end":687},"obj":"\"http://rdf.glycoinfo.org/glycan/G99522DY\""},{"id":"GlycanIUPAC_T318","span":{"begin":747,"end":750},"obj":"\"http://rdf.glycoinfo.org/glycan/G99522DY\""},{"id":"GlycanIUPAC_T319","span":{"begin":1546,"end":1549},"obj":"\"http://rdf.glycoinfo.org/glycan/G99522DY\""},{"id":"GlycanIUPAC_T320","span":{"begin":641,"end":644},"obj":"\"http://rdf.glycoinfo.org/glycan/G59246IF\""},{"id":"GlycanIUPAC_T321","span":{"begin":684,"end":687},"obj":"\"http://rdf.glycoinfo.org/glycan/G59246IF\""},{"id":"GlycanIUPAC_T322","span":{"begin":747,"end":750},"obj":"\"http://rdf.glycoinfo.org/glycan/G59246IF\""},{"id":"GlycanIUPAC_T323","span":{"begin":1546,"end":1549},"obj":"\"http://rdf.glycoinfo.org/glycan/G59246IF\""},{"id":"GlycanIUPAC_T324","span":{"begin":641,"end":644},"obj":"\"http://rdf.glycoinfo.org/glycan/G95321NT\""},{"id":"GlycanIUPAC_T325","span":{"begin":684,"end":687},"obj":"\"http://rdf.glycoinfo.org/glycan/G95321NT\""},{"id":"GlycanIUPAC_T326","span":{"begin":747,"end":750},"obj":"\"http://rdf.glycoinfo.org/glycan/G95321NT\""},{"id":"GlycanIUPAC_T327","span":{"begin":1546,"end":1549},"obj":"\"http://rdf.glycoinfo.org/glycan/G95321NT\""},{"id":"GlycanIUPAC_T328","span":{"begin":641,"end":644},"obj":"\"http://rdf.glycoinfo.org/glycan/G17531ZI\""},{"id":"GlycanIUPAC_T329","span":{"begin":684,"end":687},"obj":"\"http://rdf.glycoinfo.org/glycan/G17531ZI\""},{"id":"GlycanIUPAC_T330","span":{"begin":747,"end":750},"obj":"\"http://rdf.glycoinfo.org/glycan/G17531ZI\""},{"id":"GlycanIUPAC_T331","span":{"begin":1546,"end":1549},"obj":"\"http://rdf.glycoinfo.org/glycan/G17531ZI\""},{"id":"GlycanIUPAC_T332","span":{"begin":641,"end":644},"obj":"\"http://rdf.glycoinfo.org/glycan/G54322SU\""},{"id":"GlycanIUPAC_T333","span":{"begin":684,"end":687},"obj":"\"http://rdf.glycoinfo.org/glycan/G54322SU\""},{"id":"GlycanIUPAC_T334","span":{"begin":747,"end":750},"obj":"\"http://rdf.glycoinfo.org/glycan/G54322SU\""},{"id":"GlycanIUPAC_T335","span":{"begin":1546,"end":1549},"obj":"\"http://rdf.glycoinfo.org/glycan/G54322SU\""},{"id":"GlycanIUPAC_T336","span":{"begin":641,"end":644},"obj":"\"http://rdf.glycoinfo.org/glycan/G72010DO\""},{"id":"GlycanIUPAC_T337","span":{"begin":684,"end":687},"obj":"\"http://rdf.glycoinfo.org/glycan/G72010DO\""},{"id":"GlycanIUPAC_T338","span":{"begin":747,"end":750},"obj":"\"http://rdf.glycoinfo.org/glycan/G72010DO\""},{"id":"GlycanIUPAC_T339","span":{"begin":1546,"end":1549},"obj":"\"http://rdf.glycoinfo.org/glycan/G72010DO\""},{"id":"GlycanIUPAC_T340","span":{"begin":641,"end":644},"obj":"\"http://rdf.glycoinfo.org/glycan/G44269EP\""},{"id":"GlycanIUPAC_T341","span":{"begin":684,"end":687},"obj":"\"http://rdf.glycoinfo.org/glycan/G44269EP\""},{"id":"GlycanIUPAC_T342","span":{"begin":747,"end":750},"obj":"\"http://rdf.glycoinfo.org/glycan/G44269EP\""},{"id":"GlycanIUPAC_T343","span":{"begin":1546,"end":1549},"obj":"\"http://rdf.glycoinfo.org/glycan/G44269EP\""},{"id":"GlycanIUPAC_T344","span":{"begin":641,"end":644},"obj":"\"http://rdf.glycoinfo.org/glycan/G57335AD\""},{"id":"GlycanIUPAC_T345","span":{"begin":684,"end":687},"obj":"\"http://rdf.glycoinfo.org/glycan/G57335AD\""},{"id":"GlycanIUPAC_T346","span":{"begin":747,"end":750},"obj":"\"http://rdf.glycoinfo.org/glycan/G57335AD\""},{"id":"GlycanIUPAC_T347","span":{"begin":1546,"end":1549},"obj":"\"http://rdf.glycoinfo.org/glycan/G57335AD\""},{"id":"GlycanIUPAC_T348","span":{"begin":641,"end":644},"obj":"\"http://rdf.glycoinfo.org/glycan/G60837LL\""},{"id":"GlycanIUPAC_T349","span":{"begin":684,"end":687},"obj":"\"http://rdf.glycoinfo.org/glycan/G60837LL\""},{"id":"GlycanIUPAC_T350","span":{"begin":747,"end":750},"obj":"\"http://rdf.glycoinfo.org/glycan/G60837LL\""},{"id":"GlycanIUPAC_T351","span":{"begin":1546,"end":1549},"obj":"\"http://rdf.glycoinfo.org/glycan/G60837LL\""},{"id":"GlycanIUPAC_T352","span":{"begin":641,"end":644},"obj":"\"http://rdf.glycoinfo.org/glycan/G61929XX\""},{"id":"GlycanIUPAC_T353","span":{"begin":684,"end":687},"obj":"\"http://rdf.glycoinfo.org/glycan/G61929XX\""},{"id":"GlycanIUPAC_T354","span":{"begin":747,"end":750},"obj":"\"http://rdf.glycoinfo.org/glycan/G61929XX\""},{"id":"GlycanIUPAC_T355","span":{"begin":1546,"end":1549},"obj":"\"http://rdf.glycoinfo.org/glycan/G61929XX\""},{"id":"GlycanIUPAC_T356","span":{"begin":641,"end":644},"obj":"\"http://rdf.glycoinfo.org/glycan/G88747RA\""},{"id":"GlycanIUPAC_T357","span":{"begin":684,"end":687},"obj":"\"http://rdf.glycoinfo.org/glycan/G88747RA\""},{"id":"GlycanIUPAC_T358","span":{"begin":747,"end":750},"obj":"\"http://rdf.glycoinfo.org/glycan/G88747RA\""},{"id":"GlycanIUPAC_T359","span":{"begin":1546,"end":1549},"obj":"\"http://rdf.glycoinfo.org/glycan/G88747RA\""},{"id":"GlycanIUPAC_T360","span":{"begin":641,"end":644},"obj":"\"http://rdf.glycoinfo.org/glycan/G47955HA\""},{"id":"GlycanIUPAC_T361","span":{"begin":684,"end":687},"obj":"\"http://rdf.glycoinfo.org/glycan/G47955HA\""},{"id":"GlycanIUPAC_T362","span":{"begin":747,"end":750},"obj":"\"http://rdf.glycoinfo.org/glycan/G47955HA\""},{"id":"GlycanIUPAC_T363","span":{"begin":1546,"end":1549},"obj":"\"http://rdf.glycoinfo.org/glycan/G47955HA\""},{"id":"GlycanIUPAC_T364","span":{"begin":641,"end":644},"obj":"\"http://rdf.glycoinfo.org/glycan/G60982WS\""},{"id":"GlycanIUPAC_T365","span":{"begin":684,"end":687},"obj":"\"http://rdf.glycoinfo.org/glycan/G60982WS\""},{"id":"GlycanIUPAC_T366","span":{"begin":747,"end":750},"obj":"\"http://rdf.glycoinfo.org/glycan/G60982WS\""},{"id":"GlycanIUPAC_T367","span":{"begin":1546,"end":1549},"obj":"\"http://rdf.glycoinfo.org/glycan/G60982WS\""},{"id":"GlycanIUPAC_T368","span":{"begin":641,"end":644},"obj":"\"http://rdf.glycoinfo.org/glycan/G37035KG\""},{"id":"GlycanIUPAC_T369","span":{"begin":684,"end":687},"obj":"\"http://rdf.glycoinfo.org/glycan/G37035KG\""},{"id":"GlycanIUPAC_T370","span":{"begin":747,"end":750},"obj":"\"http://rdf.glycoinfo.org/glycan/G37035KG\""},{"id":"GlycanIUPAC_T371","span":{"begin":1546,"end":1549},"obj":"\"http://rdf.glycoinfo.org/glycan/G37035KG\""},{"id":"GlycanIUPAC_T372","span":{"begin":641,"end":644},"obj":"\"http://rdf.glycoinfo.org/glycan/G46297FI\""},{"id":"GlycanIUPAC_T373","span":{"begin":684,"end":687},"obj":"\"http://rdf.glycoinfo.org/glycan/G46297FI\""},{"id":"GlycanIUPAC_T374","span":{"begin":747,"end":750},"obj":"\"http://rdf.glycoinfo.org/glycan/G46297FI\""},{"id":"GlycanIUPAC_T375","span":{"begin":1546,"end":1549},"obj":"\"http://rdf.glycoinfo.org/glycan/G46297FI\""},{"id":"GlycanIUPAC_T376","span":{"begin":641,"end":644},"obj":"\"http://rdf.glycoinfo.org/glycan/G35475KI\""},{"id":"GlycanIUPAC_T377","span":{"begin":684,"end":687},"obj":"\"http://rdf.glycoinfo.org/glycan/G35475KI\""},{"id":"GlycanIUPAC_T378","span":{"begin":747,"end":750},"obj":"\"http://rdf.glycoinfo.org/glycan/G35475KI\""},{"id":"GlycanIUPAC_T379","span":{"begin":1546,"end":1549},"obj":"\"http://rdf.glycoinfo.org/glycan/G35475KI\""},{"id":"GlycanIUPAC_T380","span":{"begin":641,"end":644},"obj":"\"http://rdf.glycoinfo.org/glycan/G29771JN\""},{"id":"GlycanIUPAC_T381","span":{"begin":684,"end":687},"obj":"\"http://rdf.glycoinfo.org/glycan/G29771JN\""},{"id":"GlycanIUPAC_T382","span":{"begin":747,"end":750},"obj":"\"http://rdf.glycoinfo.org/glycan/G29771JN\""},{"id":"GlycanIUPAC_T383","span":{"begin":1546,"end":1549},"obj":"\"http://rdf.glycoinfo.org/glycan/G29771JN\""},{"id":"GlycanIUPAC_T384","span":{"begin":641,"end":644},"obj":"\"http://rdf.glycoinfo.org/glycan/G61285YR\""},{"id":"GlycanIUPAC_T385","span":{"begin":684,"end":687},"obj":"\"http://rdf.glycoinfo.org/glycan/G61285YR\""},{"id":"GlycanIUPAC_T386","span":{"begin":747,"end":750},"obj":"\"http://rdf.glycoinfo.org/glycan/G61285YR\""},{"id":"GlycanIUPAC_T387","span":{"begin":1546,"end":1549},"obj":"\"http://rdf.glycoinfo.org/glycan/G61285YR\""},{"id":"GlycanIUPAC_T388","span":{"begin":641,"end":644},"obj":"\"http://rdf.glycoinfo.org/glycan/G54785MW\""},{"id":"GlycanIUPAC_T389","span":{"begin":684,"end":687},"obj":"\"http://rdf.glycoinfo.org/glycan/G54785MW\""},{"id":"GlycanIUPAC_T390","span":{"begin":747,"end":750},"obj":"\"http://rdf.glycoinfo.org/glycan/G54785MW\""},{"id":"GlycanIUPAC_T391","span":{"begin":1546,"end":1549},"obj":"\"http://rdf.glycoinfo.org/glycan/G54785MW\""},{"id":"GlycanIUPAC_T392","span":{"begin":641,"end":644},"obj":"\"http://rdf.glycoinfo.org/glycan/G53039GT\""},{"id":"GlycanIUPAC_T393","span":{"begin":684,"end":687},"obj":"\"http://rdf.glycoinfo.org/glycan/G53039GT\""},{"id":"GlycanIUPAC_T394","span":{"begin":747,"end":750},"obj":"\"http://rdf.glycoinfo.org/glycan/G53039GT\""},{"id":"GlycanIUPAC_T395","span":{"begin":1546,"end":1549},"obj":"\"http://rdf.glycoinfo.org/glycan/G53039GT\""},{"id":"GlycanIUPAC_T396","span":{"begin":641,"end":644},"obj":"\"http://rdf.glycoinfo.org/glycan/G00601HK\""},{"id":"GlycanIUPAC_T397","span":{"begin":684,"end":687},"obj":"\"http://rdf.glycoinfo.org/glycan/G00601HK\""},{"id":"GlycanIUPAC_T398","span":{"begin":747,"end":750},"obj":"\"http://rdf.glycoinfo.org/glycan/G00601HK\""},{"id":"GlycanIUPAC_T399","span":{"begin":1546,"end":1549},"obj":"\"http://rdf.glycoinfo.org/glycan/G00601HK\""},{"id":"GlycanIUPAC_T400","span":{"begin":641,"end":644},"obj":"\"http://rdf.glycoinfo.org/glycan/G10485IJ\""},{"id":"GlycanIUPAC_T401","span":{"begin":684,"end":687},"obj":"\"http://rdf.glycoinfo.org/glycan/G10485IJ\""},{"id":"GlycanIUPAC_T402","span":{"begin":747,"end":750},"obj":"\"http://rdf.glycoinfo.org/glycan/G10485IJ\""},{"id":"GlycanIUPAC_T403","span":{"begin":1546,"end":1549},"obj":"\"http://rdf.glycoinfo.org/glycan/G10485IJ\""},{"id":"GlycanIUPAC_T404","span":{"begin":641,"end":644},"obj":"\"http://rdf.glycoinfo.org/glycan/G16393IB\""},{"id":"GlycanIUPAC_T405","span":{"begin":684,"end":687},"obj":"\"http://rdf.glycoinfo.org/glycan/G16393IB\""},{"id":"GlycanIUPAC_T406","span":{"begin":747,"end":750},"obj":"\"http://rdf.glycoinfo.org/glycan/G16393IB\""},{"id":"GlycanIUPAC_T407","span":{"begin":1546,"end":1549},"obj":"\"http://rdf.glycoinfo.org/glycan/G16393IB\""},{"id":"GlycanIUPAC_T408","span":{"begin":641,"end":644},"obj":"\"http://rdf.glycoinfo.org/glycan/G98436FZ\""},{"id":"GlycanIUPAC_T409","span":{"begin":684,"end":687},"obj":"\"http://rdf.glycoinfo.org/glycan/G98436FZ\""},{"id":"GlycanIUPAC_T410","span":{"begin":747,"end":750},"obj":"\"http://rdf.glycoinfo.org/glycan/G98436FZ\""},{"id":"GlycanIUPAC_T411","span":{"begin":1546,"end":1549},"obj":"\"http://rdf.glycoinfo.org/glycan/G98436FZ\""},{"id":"GlycanIUPAC_T412","span":{"begin":641,"end":644},"obj":"\"http://rdf.glycoinfo.org/glycan/G18825IA\""},{"id":"GlycanIUPAC_T413","span":{"begin":684,"end":687},"obj":"\"http://rdf.glycoinfo.org/glycan/G18825IA\""},{"id":"GlycanIUPAC_T414","span":{"begin":747,"end":750},"obj":"\"http://rdf.glycoinfo.org/glycan/G18825IA\""},{"id":"GlycanIUPAC_T415","span":{"begin":1546,"end":1549},"obj":"\"http://rdf.glycoinfo.org/glycan/G18825IA\""},{"id":"GlycanIUPAC_T416","span":{"begin":641,"end":644},"obj":"\"http://rdf.glycoinfo.org/glycan/G61281HQ\""},{"id":"GlycanIUPAC_T417","span":{"begin":684,"end":687},"obj":"\"http://rdf.glycoinfo.org/glycan/G61281HQ\""},{"id":"GlycanIUPAC_T418","span":{"begin":747,"end":750},"obj":"\"http://rdf.glycoinfo.org/glycan/G61281HQ\""},{"id":"GlycanIUPAC_T419","span":{"begin":1546,"end":1549},"obj":"\"http://rdf.glycoinfo.org/glycan/G61281HQ\""},{"id":"GlycanIUPAC_T420","span":{"begin":641,"end":644},"obj":"\"http://rdf.glycoinfo.org/glycan/G07798TI\""},{"id":"GlycanIUPAC_T421","span":{"begin":684,"end":687},"obj":"\"http://rdf.glycoinfo.org/glycan/G07798TI\""},{"id":"GlycanIUPAC_T422","span":{"begin":747,"end":750},"obj":"\"http://rdf.glycoinfo.org/glycan/G07798TI\""},{"id":"GlycanIUPAC_T423","span":{"begin":1546,"end":1549},"obj":"\"http://rdf.glycoinfo.org/glycan/G07798TI\""},{"id":"GlycanIUPAC_T424","span":{"begin":641,"end":644},"obj":"\"http://rdf.glycoinfo.org/glycan/G55921QA\""},{"id":"GlycanIUPAC_T425","span":{"begin":684,"end":687},"obj":"\"http://rdf.glycoinfo.org/glycan/G55921QA\""},{"id":"GlycanIUPAC_T426","span":{"begin":747,"end":750},"obj":"\"http://rdf.glycoinfo.org/glycan/G55921QA\""},{"id":"GlycanIUPAC_T427","span":{"begin":1546,"end":1549},"obj":"\"http://rdf.glycoinfo.org/glycan/G55921QA\""},{"id":"GlycanIUPAC_T428","span":{"begin":641,"end":644},"obj":"\"http://rdf.glycoinfo.org/glycan/G99066DL\""},{"id":"GlycanIUPAC_T429","span":{"begin":684,"end":687},"obj":"\"http://rdf.glycoinfo.org/glycan/G99066DL\""},{"id":"GlycanIUPAC_T430","span":{"begin":747,"end":750},"obj":"\"http://rdf.glycoinfo.org/glycan/G99066DL\""},{"id":"GlycanIUPAC_T431","span":{"begin":1546,"end":1549},"obj":"\"http://rdf.glycoinfo.org/glycan/G99066DL\""},{"id":"GlycanIUPAC_T432","span":{"begin":641,"end":644},"obj":"\"http://rdf.glycoinfo.org/glycan/G33451PQ\""},{"id":"GlycanIUPAC_T433","span":{"begin":684,"end":687},"obj":"\"http://rdf.glycoinfo.org/glycan/G33451PQ\""},{"id":"GlycanIUPAC_T434","span":{"begin":747,"end":750},"obj":"\"http://rdf.glycoinfo.org/glycan/G33451PQ\""},{"id":"GlycanIUPAC_T435","span":{"begin":1546,"end":1549},"obj":"\"http://rdf.glycoinfo.org/glycan/G33451PQ\""},{"id":"GlycanIUPAC_T436","span":{"begin":641,"end":644},"obj":"\"http://rdf.glycoinfo.org/glycan/G02111XU\""},{"id":"GlycanIUPAC_T437","span":{"begin":684,"end":687},"obj":"\"http://rdf.glycoinfo.org/glycan/G02111XU\""},{"id":"GlycanIUPAC_T438","span":{"begin":747,"end":750},"obj":"\"http://rdf.glycoinfo.org/glycan/G02111XU\""},{"id":"GlycanIUPAC_T439","span":{"begin":1546,"end":1549},"obj":"\"http://rdf.glycoinfo.org/glycan/G02111XU\""},{"id":"GlycanIUPAC_T440","span":{"begin":641,"end":644},"obj":"\"http://rdf.glycoinfo.org/glycan/G85193OM\""},{"id":"GlycanIUPAC_T441","span":{"begin":684,"end":687},"obj":"\"http://rdf.glycoinfo.org/glycan/G85193OM\""},{"id":"GlycanIUPAC_T442","span":{"begin":747,"end":750},"obj":"\"http://rdf.glycoinfo.org/glycan/G85193OM\""},{"id":"GlycanIUPAC_T443","span":{"begin":1546,"end":1549},"obj":"\"http://rdf.glycoinfo.org/glycan/G85193OM\""},{"id":"GlycanIUPAC_T444","span":{"begin":641,"end":644},"obj":"\"http://rdf.glycoinfo.org/glycan/G89174YQ\""},{"id":"GlycanIUPAC_T445","span":{"begin":684,"end":687},"obj":"\"http://rdf.glycoinfo.org/glycan/G89174YQ\""},{"id":"GlycanIUPAC_T446","span":{"begin":747,"end":750},"obj":"\"http://rdf.glycoinfo.org/glycan/G89174YQ\""},{"id":"GlycanIUPAC_T447","span":{"begin":1546,"end":1549},"obj":"\"http://rdf.glycoinfo.org/glycan/G89174YQ\""},{"id":"GlycanIUPAC_T448","span":{"begin":641,"end":644},"obj":"\"http://rdf.glycoinfo.org/glycan/G28802LE\""},{"id":"GlycanIUPAC_T449","span":{"begin":684,"end":687},"obj":"\"http://rdf.glycoinfo.org/glycan/G28802LE\""},{"id":"GlycanIUPAC_T450","span":{"begin":747,"end":750},"obj":"\"http://rdf.glycoinfo.org/glycan/G28802LE\""},{"id":"GlycanIUPAC_T451","span":{"begin":1546,"end":1549},"obj":"\"http://rdf.glycoinfo.org/glycan/G28802LE\""},{"id":"GlycanIUPAC_T452","span":{"begin":641,"end":644},"obj":"\"http://rdf.glycoinfo.org/glycan/G56061JK\""},{"id":"GlycanIUPAC_T453","span":{"begin":684,"end":687},"obj":"\"http://rdf.glycoinfo.org/glycan/G56061JK\""},{"id":"GlycanIUPAC_T454","span":{"begin":747,"end":750},"obj":"\"http://rdf.glycoinfo.org/glycan/G56061JK\""},{"id":"GlycanIUPAC_T455","span":{"begin":1546,"end":1549},"obj":"\"http://rdf.glycoinfo.org/glycan/G56061JK\""},{"id":"GlycanIUPAC_T456","span":{"begin":641,"end":644},"obj":"\"http://rdf.glycoinfo.org/glycan/G68941BC\""},{"id":"GlycanIUPAC_T457","span":{"begin":684,"end":687},"obj":"\"http://rdf.glycoinfo.org/glycan/G68941BC\""},{"id":"GlycanIUPAC_T458","span":{"begin":747,"end":750},"obj":"\"http://rdf.glycoinfo.org/glycan/G68941BC\""},{"id":"GlycanIUPAC_T459","span":{"begin":1546,"end":1549},"obj":"\"http://rdf.glycoinfo.org/glycan/G68941BC\""},{"id":"GlycanIUPAC_T460","span":{"begin":641,"end":644},"obj":"\"http://rdf.glycoinfo.org/glycan/G55436FC\""},{"id":"GlycanIUPAC_T461","span":{"begin":684,"end":687},"obj":"\"http://rdf.glycoinfo.org/glycan/G55436FC\""},{"id":"GlycanIUPAC_T462","span":{"begin":747,"end":750},"obj":"\"http://rdf.glycoinfo.org/glycan/G55436FC\""},{"id":"GlycanIUPAC_T463","span":{"begin":1546,"end":1549},"obj":"\"http://rdf.glycoinfo.org/glycan/G55436FC\""},{"id":"GlycanIUPAC_T464","span":{"begin":641,"end":644},"obj":"\"http://rdf.glycoinfo.org/glycan/G24002PU\""},{"id":"GlycanIUPAC_T465","span":{"begin":684,"end":687},"obj":"\"http://rdf.glycoinfo.org/glycan/G24002PU\""},{"id":"GlycanIUPAC_T466","span":{"begin":747,"end":750},"obj":"\"http://rdf.glycoinfo.org/glycan/G24002PU\""},{"id":"GlycanIUPAC_T467","span":{"begin":1546,"end":1549},"obj":"\"http://rdf.glycoinfo.org/glycan/G24002PU\""},{"id":"GlycanIUPAC_T468","span":{"begin":641,"end":644},"obj":"\"http://rdf.glycoinfo.org/glycan/G61387SV\""},{"id":"GlycanIUPAC_T469","span":{"begin":684,"end":687},"obj":"\"http://rdf.glycoinfo.org/glycan/G61387SV\""},{"id":"GlycanIUPAC_T470","span":{"begin":747,"end":750},"obj":"\"http://rdf.glycoinfo.org/glycan/G61387SV\""},{"id":"GlycanIUPAC_T471","span":{"begin":1546,"end":1549},"obj":"\"http://rdf.glycoinfo.org/glycan/G61387SV\""},{"id":"GlycanIUPAC_T472","span":{"begin":641,"end":644},"obj":"\"http://rdf.glycoinfo.org/glycan/G31834HW\""},{"id":"GlycanIUPAC_T473","span":{"begin":684,"end":687},"obj":"\"http://rdf.glycoinfo.org/glycan/G31834HW\""},{"id":"GlycanIUPAC_T474","span":{"begin":747,"end":750},"obj":"\"http://rdf.glycoinfo.org/glycan/G31834HW\""},{"id":"GlycanIUPAC_T475","span":{"begin":1546,"end":1549},"obj":"\"http://rdf.glycoinfo.org/glycan/G31834HW\""},{"id":"GlycanIUPAC_T476","span":{"begin":641,"end":644},"obj":"\"http://rdf.glycoinfo.org/glycan/G35324RT\""},{"id":"GlycanIUPAC_T477","span":{"begin":684,"end":687},"obj":"\"http://rdf.glycoinfo.org/glycan/G35324RT\""},{"id":"GlycanIUPAC_T478","span":{"begin":747,"end":750},"obj":"\"http://rdf.glycoinfo.org/glycan/G35324RT\""},{"id":"GlycanIUPAC_T479","span":{"begin":1546,"end":1549},"obj":"\"http://rdf.glycoinfo.org/glycan/G35324RT\""},{"id":"GlycanIUPAC_T480","span":{"begin":641,"end":644},"obj":"\"http://rdf.glycoinfo.org/glycan/G34803QO\""},{"id":"GlycanIUPAC_T481","span":{"begin":684,"end":687},"obj":"\"http://rdf.glycoinfo.org/glycan/G34803QO\""},{"id":"GlycanIUPAC_T482","span":{"begin":747,"end":750},"obj":"\"http://rdf.glycoinfo.org/glycan/G34803QO\""},{"id":"GlycanIUPAC_T483","span":{"begin":1546,"end":1549},"obj":"\"http://rdf.glycoinfo.org/glycan/G34803QO\""},{"id":"GlycanIUPAC_T484","span":{"begin":641,"end":644},"obj":"\"http://rdf.glycoinfo.org/glycan/G92898FF\""},{"id":"GlycanIUPAC_T485","span":{"begin":684,"end":687},"obj":"\"http://rdf.glycoinfo.org/glycan/G92898FF\""},{"id":"GlycanIUPAC_T486","span":{"begin":747,"end":750},"obj":"\"http://rdf.glycoinfo.org/glycan/G92898FF\""},{"id":"GlycanIUPAC_T487","span":{"begin":1546,"end":1549},"obj":"\"http://rdf.glycoinfo.org/glycan/G92898FF\""},{"id":"GlycanIUPAC_T488","span":{"begin":641,"end":644},"obj":"\"http://rdf.glycoinfo.org/glycan/G01318VX\""},{"id":"GlycanIUPAC_T489","span":{"begin":684,"end":687},"obj":"\"http://rdf.glycoinfo.org/glycan/G01318VX\""},{"id":"GlycanIUPAC_T490","span":{"begin":747,"end":750},"obj":"\"http://rdf.glycoinfo.org/glycan/G01318VX\""},{"id":"GlycanIUPAC_T491","span":{"begin":1546,"end":1549},"obj":"\"http://rdf.glycoinfo.org/glycan/G01318VX\""},{"id":"GlycanIUPAC_T492","span":{"begin":641,"end":644},"obj":"\"http://rdf.glycoinfo.org/glycan/G83200MX\""},{"id":"GlycanIUPAC_T493","span":{"begin":684,"end":687},"obj":"\"http://rdf.glycoinfo.org/glycan/G83200MX\""},{"id":"GlycanIUPAC_T494","span":{"begin":747,"end":750},"obj":"\"http://rdf.glycoinfo.org/glycan/G83200MX\""},{"id":"GlycanIUPAC_T495","span":{"begin":1546,"end":1549},"obj":"\"http://rdf.glycoinfo.org/glycan/G83200MX\""},{"id":"GlycanIUPAC_T496","span":{"begin":641,"end":644},"obj":"\"http://rdf.glycoinfo.org/glycan/G56286UC\""},{"id":"GlycanIUPAC_T497","span":{"begin":684,"end":687},"obj":"\"http://rdf.glycoinfo.org/glycan/G56286UC\""},{"id":"GlycanIUPAC_T498","span":{"begin":747,"end":750},"obj":"\"http://rdf.glycoinfo.org/glycan/G56286UC\""},{"id":"GlycanIUPAC_T499","span":{"begin":1546,"end":1549},"obj":"\"http://rdf.glycoinfo.org/glycan/G56286UC\""},{"id":"GlycanIUPAC_T500","span":{"begin":641,"end":644},"obj":"\"http://rdf.glycoinfo.org/glycan/G07304QA\""},{"id":"GlycanIUPAC_T501","span":{"begin":684,"end":687},"obj":"\"http://rdf.glycoinfo.org/glycan/G07304QA\""},{"id":"GlycanIUPAC_T502","span":{"begin":747,"end":750},"obj":"\"http://rdf.glycoinfo.org/glycan/G07304QA\""},{"id":"GlycanIUPAC_T503","span":{"begin":1546,"end":1549},"obj":"\"http://rdf.glycoinfo.org/glycan/G07304QA\""},{"id":"GlycanIUPAC_T504","span":{"begin":641,"end":644},"obj":"\"http://rdf.glycoinfo.org/glycan/G06868OU\""},{"id":"GlycanIUPAC_T505","span":{"begin":684,"end":687},"obj":"\"http://rdf.glycoinfo.org/glycan/G06868OU\""},{"id":"GlycanIUPAC_T506","span":{"begin":747,"end":750},"obj":"\"http://rdf.glycoinfo.org/glycan/G06868OU\""},{"id":"GlycanIUPAC_T507","span":{"begin":1546,"end":1549},"obj":"\"http://rdf.glycoinfo.org/glycan/G06868OU\""},{"id":"GlycanIUPAC_T508","span":{"begin":641,"end":644},"obj":"\"http://rdf.glycoinfo.org/glycan/G12647BS\""},{"id":"GlycanIUPAC_T509","span":{"begin":684,"end":687},"obj":"\"http://rdf.glycoinfo.org/glycan/G12647BS\""},{"id":"GlycanIUPAC_T510","span":{"begin":747,"end":750},"obj":"\"http://rdf.glycoinfo.org/glycan/G12647BS\""},{"id":"GlycanIUPAC_T511","span":{"begin":1546,"end":1549},"obj":"\"http://rdf.glycoinfo.org/glycan/G12647BS\""},{"id":"GlycanIUPAC_T512","span":{"begin":641,"end":644},"obj":"\"http://rdf.glycoinfo.org/glycan/G51841DF\""},{"id":"GlycanIUPAC_T513","span":{"begin":684,"end":687},"obj":"\"http://rdf.glycoinfo.org/glycan/G51841DF\""},{"id":"GlycanIUPAC_T514","span":{"begin":747,"end":750},"obj":"\"http://rdf.glycoinfo.org/glycan/G51841DF\""},{"id":"GlycanIUPAC_T515","span":{"begin":1546,"end":1549},"obj":"\"http://rdf.glycoinfo.org/glycan/G51841DF\""},{"id":"GlycanIUPAC_T516","span":{"begin":641,"end":644},"obj":"\"http://rdf.glycoinfo.org/glycan/G32122AJ\""},{"id":"GlycanIUPAC_T517","span":{"begin":684,"end":687},"obj":"\"http://rdf.glycoinfo.org/glycan/G32122AJ\""},{"id":"GlycanIUPAC_T518","span":{"begin":747,"end":750},"obj":"\"http://rdf.glycoinfo.org/glycan/G32122AJ\""},{"id":"GlycanIUPAC_T519","span":{"begin":1546,"end":1549},"obj":"\"http://rdf.glycoinfo.org/glycan/G32122AJ\""},{"id":"GlycanIUPAC_T520","span":{"begin":641,"end":644},"obj":"\"http://rdf.glycoinfo.org/glycan/G41125MN\""},{"id":"GlycanIUPAC_T521","span":{"begin":684,"end":687},"obj":"\"http://rdf.glycoinfo.org/glycan/G41125MN\""},{"id":"GlycanIUPAC_T522","span":{"begin":747,"end":750},"obj":"\"http://rdf.glycoinfo.org/glycan/G41125MN\""},{"id":"GlycanIUPAC_T523","span":{"begin":1546,"end":1549},"obj":"\"http://rdf.glycoinfo.org/glycan/G41125MN\""},{"id":"GlycanIUPAC_T524","span":{"begin":641,"end":644},"obj":"\"http://rdf.glycoinfo.org/glycan/G16093XS\""},{"id":"GlycanIUPAC_T525","span":{"begin":684,"end":687},"obj":"\"http://rdf.glycoinfo.org/glycan/G16093XS\""},{"id":"GlycanIUPAC_T526","span":{"begin":747,"end":750},"obj":"\"http://rdf.glycoinfo.org/glycan/G16093XS\""},{"id":"GlycanIUPAC_T527","span":{"begin":1546,"end":1549},"obj":"\"http://rdf.glycoinfo.org/glycan/G16093XS\""},{"id":"GlycanIUPAC_T528","span":{"begin":641,"end":644},"obj":"\"http://rdf.glycoinfo.org/glycan/G62425IX\""},{"id":"GlycanIUPAC_T529","span":{"begin":684,"end":687},"obj":"\"http://rdf.glycoinfo.org/glycan/G62425IX\""},{"id":"GlycanIUPAC_T530","span":{"begin":747,"end":750},"obj":"\"http://rdf.glycoinfo.org/glycan/G62425IX\""},{"id":"GlycanIUPAC_T531","span":{"begin":1546,"end":1549},"obj":"\"http://rdf.glycoinfo.org/glycan/G62425IX\""},{"id":"GlycanIUPAC_T532","span":{"begin":641,"end":644},"obj":"\"http://rdf.glycoinfo.org/glycan/G15673TO\""},{"id":"GlycanIUPAC_T533","span":{"begin":684,"end":687},"obj":"\"http://rdf.glycoinfo.org/glycan/G15673TO\""},{"id":"GlycanIUPAC_T534","span":{"begin":747,"end":750},"obj":"\"http://rdf.glycoinfo.org/glycan/G15673TO\""},{"id":"GlycanIUPAC_T535","span":{"begin":1546,"end":1549},"obj":"\"http://rdf.glycoinfo.org/glycan/G15673TO\""},{"id":"GlycanIUPAC_T536","span":{"begin":641,"end":644},"obj":"\"http://rdf.glycoinfo.org/glycan/G32857IK\""},{"id":"GlycanIUPAC_T537","span":{"begin":684,"end":687},"obj":"\"http://rdf.glycoinfo.org/glycan/G32857IK\""},{"id":"GlycanIUPAC_T538","span":{"begin":747,"end":750},"obj":"\"http://rdf.glycoinfo.org/glycan/G32857IK\""},{"id":"GlycanIUPAC_T539","span":{"begin":1546,"end":1549},"obj":"\"http://rdf.glycoinfo.org/glycan/G32857IK\""},{"id":"GlycanIUPAC_T540","span":{"begin":641,"end":644},"obj":"\"http://rdf.glycoinfo.org/glycan/G60047CJ\""},{"id":"GlycanIUPAC_T541","span":{"begin":684,"end":687},"obj":"\"http://rdf.glycoinfo.org/glycan/G60047CJ\""},{"id":"GlycanIUPAC_T542","span":{"begin":747,"end":750},"obj":"\"http://rdf.glycoinfo.org/glycan/G60047CJ\""},{"id":"GlycanIUPAC_T543","span":{"begin":1546,"end":1549},"obj":"\"http://rdf.glycoinfo.org/glycan/G60047CJ\""},{"id":"GlycanIUPAC_T544","span":{"begin":641,"end":644},"obj":"\"http://rdf.glycoinfo.org/glycan/G55718ZB\""},{"id":"GlycanIUPAC_T545","span":{"begin":684,"end":687},"obj":"\"http://rdf.glycoinfo.org/glycan/G55718ZB\""},{"id":"GlycanIUPAC_T546","span":{"begin":747,"end":750},"obj":"\"http://rdf.glycoinfo.org/glycan/G55718ZB\""},{"id":"GlycanIUPAC_T547","span":{"begin":1546,"end":1549},"obj":"\"http://rdf.glycoinfo.org/glycan/G55718ZB\""},{"id":"GlycanIUPAC_T548","span":{"begin":641,"end":644},"obj":"\"http://rdf.glycoinfo.org/glycan/G88355ZE\""},{"id":"GlycanIUPAC_T549","span":{"begin":684,"end":687},"obj":"\"http://rdf.glycoinfo.org/glycan/G88355ZE\""},{"id":"GlycanIUPAC_T550","span":{"begin":747,"end":750},"obj":"\"http://rdf.glycoinfo.org/glycan/G88355ZE\""},{"id":"GlycanIUPAC_T551","span":{"begin":1546,"end":1549},"obj":"\"http://rdf.glycoinfo.org/glycan/G88355ZE\""},{"id":"GlycanIUPAC_T552","span":{"begin":641,"end":644},"obj":"\"http://rdf.glycoinfo.org/glycan/G11283PA\""},{"id":"GlycanIUPAC_T553","span":{"begin":684,"end":687},"obj":"\"http://rdf.glycoinfo.org/glycan/G11283PA\""},{"id":"GlycanIUPAC_T554","span":{"begin":747,"end":750},"obj":"\"http://rdf.glycoinfo.org/glycan/G11283PA\""},{"id":"GlycanIUPAC_T555","span":{"begin":1546,"end":1549},"obj":"\"http://rdf.glycoinfo.org/glycan/G11283PA\""},{"id":"GlycanIUPAC_T556","span":{"begin":641,"end":644},"obj":"\"http://rdf.glycoinfo.org/glycan/G71737IZ\""},{"id":"GlycanIUPAC_T557","span":{"begin":684,"end":687},"obj":"\"http://rdf.glycoinfo.org/glycan/G71737IZ\""},{"id":"GlycanIUPAC_T558","span":{"begin":747,"end":750},"obj":"\"http://rdf.glycoinfo.org/glycan/G71737IZ\""},{"id":"GlycanIUPAC_T559","span":{"begin":1546,"end":1549},"obj":"\"http://rdf.glycoinfo.org/glycan/G71737IZ\""},{"id":"GlycanIUPAC_T560","span":{"begin":641,"end":644},"obj":"\"http://rdf.glycoinfo.org/glycan/G60912WZ\""},{"id":"GlycanIUPAC_T561","span":{"begin":684,"end":687},"obj":"\"http://rdf.glycoinfo.org/glycan/G60912WZ\""},{"id":"GlycanIUPAC_T562","span":{"begin":747,"end":750},"obj":"\"http://rdf.glycoinfo.org/glycan/G60912WZ\""},{"id":"GlycanIUPAC_T563","span":{"begin":1546,"end":1549},"obj":"\"http://rdf.glycoinfo.org/glycan/G60912WZ\""},{"id":"GlycanIUPAC_T564","span":{"begin":641,"end":644},"obj":"\"http://rdf.glycoinfo.org/glycan/G99655SO\""},{"id":"GlycanIUPAC_T565","span":{"begin":684,"end":687},"obj":"\"http://rdf.glycoinfo.org/glycan/G99655SO\""},{"id":"GlycanIUPAC_T566","span":{"begin":747,"end":750},"obj":"\"http://rdf.glycoinfo.org/glycan/G99655SO\""},{"id":"GlycanIUPAC_T567","span":{"begin":1546,"end":1549},"obj":"\"http://rdf.glycoinfo.org/glycan/G99655SO\""},{"id":"GlycanIUPAC_T568","span":{"begin":641,"end":644},"obj":"\"http://rdf.glycoinfo.org/glycan/G10300TW\""},{"id":"GlycanIUPAC_T569","span":{"begin":684,"end":687},"obj":"\"http://rdf.glycoinfo.org/glycan/G10300TW\""},{"id":"GlycanIUPAC_T570","span":{"begin":747,"end":750},"obj":"\"http://rdf.glycoinfo.org/glycan/G10300TW\""},{"id":"GlycanIUPAC_T571","span":{"begin":1546,"end":1549},"obj":"\"http://rdf.glycoinfo.org/glycan/G10300TW\""},{"id":"GlycanIUPAC_T572","span":{"begin":641,"end":644},"obj":"\"http://rdf.glycoinfo.org/glycan/G89509FL\""},{"id":"GlycanIUPAC_T573","span":{"begin":684,"end":687},"obj":"\"http://rdf.glycoinfo.org/glycan/G89509FL\""},{"id":"GlycanIUPAC_T574","span":{"begin":747,"end":750},"obj":"\"http://rdf.glycoinfo.org/glycan/G89509FL\""},{"id":"GlycanIUPAC_T575","span":{"begin":1546,"end":1549},"obj":"\"http://rdf.glycoinfo.org/glycan/G89509FL\""},{"id":"GlycanIUPAC_T576","span":{"begin":641,"end":644},"obj":"\"http://rdf.glycoinfo.org/glycan/G31465TH\""},{"id":"GlycanIUPAC_T577","span":{"begin":684,"end":687},"obj":"\"http://rdf.glycoinfo.org/glycan/G31465TH\""},{"id":"GlycanIUPAC_T578","span":{"begin":747,"end":750},"obj":"\"http://rdf.glycoinfo.org/glycan/G31465TH\""},{"id":"GlycanIUPAC_T579","span":{"begin":1546,"end":1549},"obj":"\"http://rdf.glycoinfo.org/glycan/G31465TH\""},{"id":"GlycanIUPAC_T580","span":{"begin":641,"end":644},"obj":"\"http://rdf.glycoinfo.org/glycan/G94101LU\""},{"id":"GlycanIUPAC_T581","span":{"begin":684,"end":687},"obj":"\"http://rdf.glycoinfo.org/glycan/G94101LU\""},{"id":"GlycanIUPAC_T582","span":{"begin":747,"end":750},"obj":"\"http://rdf.glycoinfo.org/glycan/G94101LU\""},{"id":"GlycanIUPAC_T583","span":{"begin":1546,"end":1549},"obj":"\"http://rdf.glycoinfo.org/glycan/G94101LU\""},{"id":"GlycanIUPAC_T584","span":{"begin":641,"end":644},"obj":"\"http://rdf.glycoinfo.org/glycan/G38610BB\""},{"id":"GlycanIUPAC_T585","span":{"begin":684,"end":687},"obj":"\"http://rdf.glycoinfo.org/glycan/G38610BB\""},{"id":"GlycanIUPAC_T586","span":{"begin":747,"end":750},"obj":"\"http://rdf.glycoinfo.org/glycan/G38610BB\""},{"id":"GlycanIUPAC_T587","span":{"begin":1546,"end":1549},"obj":"\"http://rdf.glycoinfo.org/glycan/G38610BB\""},{"id":"GlycanIUPAC_T588","span":{"begin":641,"end":644},"obj":"\"http://rdf.glycoinfo.org/glycan/G85893UF\""},{"id":"GlycanIUPAC_T589","span":{"begin":684,"end":687},"obj":"\"http://rdf.glycoinfo.org/glycan/G85893UF\""},{"id":"GlycanIUPAC_T590","span":{"begin":747,"end":750},"obj":"\"http://rdf.glycoinfo.org/glycan/G85893UF\""},{"id":"GlycanIUPAC_T591","span":{"begin":1546,"end":1549},"obj":"\"http://rdf.glycoinfo.org/glycan/G85893UF\""},{"id":"GlycanIUPAC_T592","span":{"begin":1694,"end":1700},"obj":"\"http://rdf.glycoinfo.org/glycan/G26693XF\""},{"id":"GlycanIUPAC_T593","span":{"begin":1694,"end":1700},"obj":"\"http://rdf.glycoinfo.org/glycan/G01864SU\""},{"id":"GlycanIUPAC_T594","span":{"begin":1694,"end":1700},"obj":"\"http://rdf.glycoinfo.org/glycan/G17605FD\""},{"id":"GlycanIUPAC_T595","span":{"begin":1694,"end":1700},"obj":"\"http://rdf.glycoinfo.org/glycan/G41950LU\""},{"id":"GlycanIUPAC_T596","span":{"begin":1694,"end":1700},"obj":"\"http://rdf.glycoinfo.org/glycan/G57195RJ\""},{"id":"GlycanIUPAC_T597","span":{"begin":1694,"end":1700},"obj":"\"http://rdf.glycoinfo.org/glycan/G85391SA\""},{"id":"GlycanIUPAC_T598","span":{"begin":1694,"end":1700},"obj":"\"http://rdf.glycoinfo.org/glycan/G89565QL\""},{"id":"GlycanIUPAC_T599","span":{"begin":1694,"end":1700},"obj":"\"http://rdf.glycoinfo.org/glycan/G80869MR\""},{"id":"GlycanIUPAC_T600","span":{"begin":1694,"end":1700},"obj":"\"http://rdf.glycoinfo.org/glycan/G55978NL\""},{"id":"GlycanIUPAC_T601","span":{"begin":1694,"end":1700},"obj":"\"http://rdf.glycoinfo.org/glycan/G54644LT\""},{"id":"GlycanIUPAC_T602","span":{"begin":1694,"end":1700},"obj":"\"http://rdf.glycoinfo.org/glycan/G25694UG\""},{"id":"GlycanIUPAC_T603","span":{"begin":1694,"end":1700},"obj":"\"http://rdf.glycoinfo.org/glycan/G25126RB\""},{"id":"GlycanIUPAC_T604","span":{"begin":1694,"end":1700},"obj":"\"http://rdf.glycoinfo.org/glycan/G51848AD\""},{"id":"GlycanIUPAC_T605","span":{"begin":1694,"end":1700},"obj":"\"http://rdf.glycoinfo.org/glycan/G94667GM\""},{"id":"GlycanIUPAC_T606","span":{"begin":1694,"end":1700},"obj":"\"http://rdf.glycoinfo.org/glycan/G30124BO\""},{"id":"GlycanIUPAC_T607","span":{"begin":1694,"end":1700},"obj":"\"http://rdf.glycoinfo.org/glycan/G82777EZ\""},{"id":"GlycanIUPAC_T608","span":{"begin":1694,"end":1700},"obj":"\"http://rdf.glycoinfo.org/glycan/G10151YZ\""},{"id":"GlycanIUPAC_T609","span":{"begin":1694,"end":1700},"obj":"\"http://rdf.glycoinfo.org/glycan/G17585ZM\""},{"id":"GlycanIUPAC_T610","span":{"begin":1694,"end":1700},"obj":"\"http://rdf.glycoinfo.org/glycan/G04411CJ\""},{"id":"GlycanIUPAC_T611","span":{"begin":1694,"end":1700},"obj":"\"http://rdf.glycoinfo.org/glycan/G38254HJ\""},{"id":"GlycanIUPAC_T612","span":{"begin":1694,"end":1700},"obj":"\"http://rdf.glycoinfo.org/glycan/G75188FS\""},{"id":"GlycanIUPAC_T613","span":{"begin":1694,"end":1700},"obj":"\"http://rdf.glycoinfo.org/glycan/G70374VG\""},{"id":"GlycanIUPAC_T614","span":{"begin":1694,"end":1700},"obj":"\"http://rdf.glycoinfo.org/glycan/G45176LJ\""},{"id":"GlycanIUPAC_T615","span":{"begin":1694,"end":1700},"obj":"\"http://rdf.glycoinfo.org/glycan/G30874VW\""},{"id":"GlycanIUPAC_T616","span":{"begin":1694,"end":1700},"obj":"\"http://rdf.glycoinfo.org/glycan/G69333MI\""},{"id":"GlycanIUPAC_T617","span":{"begin":1694,"end":1700},"obj":"\"http://rdf.glycoinfo.org/glycan/G10676XO\""},{"id":"GlycanIUPAC_T618","span":{"begin":1694,"end":1700},"obj":"\"http://rdf.glycoinfo.org/glycan/G14843DJ\""},{"id":"GlycanIUPAC_T619","span":{"begin":1694,"end":1700},"obj":"\"http://rdf.glycoinfo.org/glycan/G47546FR\""},{"id":"GlycanIUPAC_T620","span":{"begin":1694,"end":1700},"obj":"\"http://rdf.glycoinfo.org/glycan/G73695ZM\""},{"id":"GlycanIUPAC_T621","span":{"begin":1694,"end":1700},"obj":"\"http://rdf.glycoinfo.org/glycan/G31923TJ\""},{"id":"GlycanIUPAC_T622","span":{"begin":1694,"end":1700},"obj":"\"http://rdf.glycoinfo.org/glycan/G60519EP\""},{"id":"GlycanIUPAC_T623","span":{"begin":1694,"end":1700},"obj":"\"http://rdf.glycoinfo.org/glycan/G07933IA\""},{"id":"GlycanIUPAC_T624","span":{"begin":1694,"end":1700},"obj":"\"http://rdf.glycoinfo.org/glycan/G40745NH\""},{"id":"GlycanIUPAC_T625","span":{"begin":1694,"end":1700},"obj":"\"http://rdf.glycoinfo.org/glycan/G54496YV\""},{"id":"GlycanIUPAC_T626","span":{"begin":1694,"end":1700},"obj":"\"http://rdf.glycoinfo.org/glycan/G62953SQ\""},{"id":"GlycanIUPAC_T627","span":{"begin":1694,"end":1700},"obj":"\"http://rdf.glycoinfo.org/glycan/G70070AY\""},{"id":"GlycanIUPAC_T628","span":{"begin":1694,"end":1700},"obj":"\"http://rdf.glycoinfo.org/glycan/G78792WC\""},{"id":"GlycanIUPAC_T629","span":{"begin":1694,"end":1700},"obj":"\"http://rdf.glycoinfo.org/glycan/G25238AV\""},{"id":"GlycanIUPAC_T630","span":{"begin":1694,"end":1700},"obj":"\"http://rdf.glycoinfo.org/glycan/G40510DP\""},{"id":"GlycanIUPAC_T631","span":{"begin":1694,"end":1700},"obj":"\"http://rdf.glycoinfo.org/glycan/G61120TK\""},{"id":"GlycanIUPAC_T632","span":{"begin":1694,"end":1700},"obj":"\"http://rdf.glycoinfo.org/glycan/G41342KV\""},{"id":"GlycanIUPAC_T633","span":{"begin":1694,"end":1700},"obj":"\"http://rdf.glycoinfo.org/glycan/G90703NA\""},{"id":"GlycanIUPAC_T634","span":{"begin":1694,"end":1700},"obj":"\"http://rdf.glycoinfo.org/glycan/G01591HR\""},{"id":"GlycanIUPAC_T635","span":{"begin":1694,"end":1700},"obj":"\"http://rdf.glycoinfo.org/glycan/G56520XN\""},{"id":"GlycanIUPAC_T636","span":{"begin":1694,"end":1700},"obj":"\"http://rdf.glycoinfo.org/glycan/G81830JX\""}],"text":"Novel immunogenicity of Thomsen-Friedenreich disaccharide obtained by a molecular rotation on its carrier linkage.\nThe alpha-anomeric Galbeta1-3GalNAc, called Thomsen-Friedenreich disaccharide (TFD), is overexpressed in epithelial cancer cells by aberrant O-glycosylation. TFD is also the main ligand of Agaricus bisporus lectin (ABL), a reversible noncytotoxic inhibitor of proliferation of epithelial cell lines. In order to obtain anti-TFD antibody response with a fine carbohydrate-binding specificity similar to that of ABL, we designed an immunogen of TFD with a molecular rotation on its carrier linkage that exposes more GalNAc than Gal, since ABL recognizes GalNAc more than Gal in TFD. The synthesis was accomplished by C-6 oxidation of Gal from TFD or its alpha-benzyl derivative (BzlalphaTFD), followed by reductive amination between the C-6 aldehyde yielded and the available amine of protein. Mice immunized with TFD-KLH (keyhole limpet hemocyanin) or BzlalphaTFD-KLH produced antibodies which were then analyzed by ELISA against several target antigens. Both immunogens raised anti-KLH antibody titers; however, TFD-KLH did not raise anti-TFD antibodies showing low TFD immunogenicity. In contrast, BzlalphaTFD-KLH gave much higher anti-TFD antibody response, indicating that benzyl residue helps improve anti-carbohydrate immune response. When IgG and IgM anti-TFD antibodies were analyzed by competitive ELISA using TFD-related carbohydrates as inhibitors, a high specificity to TFD as well as an enhanced binding to GalNAc over Gal were observed. The axial C-4 hydroxyl group of GalNAc interacted with IgG anti-TFD antibody, as evidenced by the lack of inhibitory activity of GlcNAc in contrast to GalNAc. These findings indicate that the anti-TFD antibodies have fine carbohydrate-binding specificity more similar to ABL than to other TFD-binding proteins that stimulate proliferation of epithelial cell lines."}

    Lectin

    {"project":"Lectin","denotations":[{"id":"Lectin_T1","span":{"begin":330,"end":333},"obj":"https://acgg.asia/db/lfdb/LfDB0126"},{"id":"Lectin_T2","span":{"begin":525,"end":528},"obj":"https://acgg.asia/db/lfdb/LfDB0126"},{"id":"Lectin_T3","span":{"begin":652,"end":655},"obj":"https://acgg.asia/db/lfdb/LfDB0126"},{"id":"Lectin_T4","span":{"begin":1836,"end":1839},"obj":"https://acgg.asia/db/lfdb/LfDB0126"}],"text":"Novel immunogenicity of Thomsen-Friedenreich disaccharide obtained by a molecular rotation on its carrier linkage.\nThe alpha-anomeric Galbeta1-3GalNAc, called Thomsen-Friedenreich disaccharide (TFD), is overexpressed in epithelial cancer cells by aberrant O-glycosylation. TFD is also the main ligand of Agaricus bisporus lectin (ABL), a reversible noncytotoxic inhibitor of proliferation of epithelial cell lines. In order to obtain anti-TFD antibody response with a fine carbohydrate-binding specificity similar to that of ABL, we designed an immunogen of TFD with a molecular rotation on its carrier linkage that exposes more GalNAc than Gal, since ABL recognizes GalNAc more than Gal in TFD. The synthesis was accomplished by C-6 oxidation of Gal from TFD or its alpha-benzyl derivative (BzlalphaTFD), followed by reductive amination between the C-6 aldehyde yielded and the available amine of protein. Mice immunized with TFD-KLH (keyhole limpet hemocyanin) or BzlalphaTFD-KLH produced antibodies which were then analyzed by ELISA against several target antigens. Both immunogens raised anti-KLH antibody titers; however, TFD-KLH did not raise anti-TFD antibodies showing low TFD immunogenicity. In contrast, BzlalphaTFD-KLH gave much higher anti-TFD antibody response, indicating that benzyl residue helps improve anti-carbohydrate immune response. When IgG and IgM anti-TFD antibodies were analyzed by competitive ELISA using TFD-related carbohydrates as inhibitors, a high specificity to TFD as well as an enhanced binding to GalNAc over Gal were observed. The axial C-4 hydroxyl group of GalNAc interacted with IgG anti-TFD antibody, as evidenced by the lack of inhibitory activity of GlcNAc in contrast to GalNAc. These findings indicate that the anti-TFD antibodies have fine carbohydrate-binding specificity more similar to ABL than to other TFD-binding proteins that stimulate proliferation of epithelial cell lines."}

    mondo_disease

    {"project":"mondo_disease","denotations":[{"id":"T1","span":{"begin":231,"end":237},"obj":"Disease"},{"id":"T2","span":{"begin":330,"end":333},"obj":"Disease"},{"id":"T3","span":{"begin":525,"end":528},"obj":"Disease"},{"id":"T4","span":{"begin":652,"end":655},"obj":"Disease"},{"id":"T5","span":{"begin":1836,"end":1839},"obj":"Disease"}],"attributes":[{"id":"A1","pred":"mondo_id","subj":"T1","obj":"http://purl.obolibrary.org/obo/MONDO_0004992"},{"id":"A2","pred":"mondo_id","subj":"T2","obj":"http://purl.obolibrary.org/obo/MONDO_0008692"},{"id":"A3","pred":"mondo_id","subj":"T3","obj":"http://purl.obolibrary.org/obo/MONDO_0008692"},{"id":"A4","pred":"mondo_id","subj":"T4","obj":"http://purl.obolibrary.org/obo/MONDO_0008692"},{"id":"A5","pred":"mondo_id","subj":"T5","obj":"http://purl.obolibrary.org/obo/MONDO_0008692"}],"text":"Novel immunogenicity of Thomsen-Friedenreich disaccharide obtained by a molecular rotation on its carrier linkage.\nThe alpha-anomeric Galbeta1-3GalNAc, called Thomsen-Friedenreich disaccharide (TFD), is overexpressed in epithelial cancer cells by aberrant O-glycosylation. TFD is also the main ligand of Agaricus bisporus lectin (ABL), a reversible noncytotoxic inhibitor of proliferation of epithelial cell lines. In order to obtain anti-TFD antibody response with a fine carbohydrate-binding specificity similar to that of ABL, we designed an immunogen of TFD with a molecular rotation on its carrier linkage that exposes more GalNAc than Gal, since ABL recognizes GalNAc more than Gal in TFD. The synthesis was accomplished by C-6 oxidation of Gal from TFD or its alpha-benzyl derivative (BzlalphaTFD), followed by reductive amination between the C-6 aldehyde yielded and the available amine of protein. Mice immunized with TFD-KLH (keyhole limpet hemocyanin) or BzlalphaTFD-KLH produced antibodies which were then analyzed by ELISA against several target antigens. Both immunogens raised anti-KLH antibody titers; however, TFD-KLH did not raise anti-TFD antibodies showing low TFD immunogenicity. In contrast, BzlalphaTFD-KLH gave much higher anti-TFD antibody response, indicating that benzyl residue helps improve anti-carbohydrate immune response. When IgG and IgM anti-TFD antibodies were analyzed by competitive ELISA using TFD-related carbohydrates as inhibitors, a high specificity to TFD as well as an enhanced binding to GalNAc over Gal were observed. The axial C-4 hydroxyl group of GalNAc interacted with IgG anti-TFD antibody, as evidenced by the lack of inhibitory activity of GlcNAc in contrast to GalNAc. These findings indicate that the anti-TFD antibodies have fine carbohydrate-binding specificity more similar to ABL than to other TFD-binding proteins that stimulate proliferation of epithelial cell lines."}

    HP-phenotype

    {"project":"HP-phenotype","denotations":[{"id":"T1","span":{"begin":231,"end":237},"obj":"Phenotype"}],"attributes":[{"id":"A1","pred":"hp_id","subj":"T1","obj":"HP:0002664"}],"namespaces":[{"prefix":"HP","uri":"http://purl.obolibrary.org/obo/HP_"}],"text":"Novel immunogenicity of Thomsen-Friedenreich disaccharide obtained by a molecular rotation on its carrier linkage.\nThe alpha-anomeric Galbeta1-3GalNAc, called Thomsen-Friedenreich disaccharide (TFD), is overexpressed in epithelial cancer cells by aberrant O-glycosylation. TFD is also the main ligand of Agaricus bisporus lectin (ABL), a reversible noncytotoxic inhibitor of proliferation of epithelial cell lines. In order to obtain anti-TFD antibody response with a fine carbohydrate-binding specificity similar to that of ABL, we designed an immunogen of TFD with a molecular rotation on its carrier linkage that exposes more GalNAc than Gal, since ABL recognizes GalNAc more than Gal in TFD. The synthesis was accomplished by C-6 oxidation of Gal from TFD or its alpha-benzyl derivative (BzlalphaTFD), followed by reductive amination between the C-6 aldehyde yielded and the available amine of protein. Mice immunized with TFD-KLH (keyhole limpet hemocyanin) or BzlalphaTFD-KLH produced antibodies which were then analyzed by ELISA against several target antigens. Both immunogens raised anti-KLH antibody titers; however, TFD-KLH did not raise anti-TFD antibodies showing low TFD immunogenicity. In contrast, BzlalphaTFD-KLH gave much higher anti-TFD antibody response, indicating that benzyl residue helps improve anti-carbohydrate immune response. When IgG and IgM anti-TFD antibodies were analyzed by competitive ELISA using TFD-related carbohydrates as inhibitors, a high specificity to TFD as well as an enhanced binding to GalNAc over Gal were observed. The axial C-4 hydroxyl group of GalNAc interacted with IgG anti-TFD antibody, as evidenced by the lack of inhibitory activity of GlcNAc in contrast to GalNAc. These findings indicate that the anti-TFD antibodies have fine carbohydrate-binding specificity more similar to ABL than to other TFD-binding proteins that stimulate proliferation of epithelial cell lines."}

    Glycan-GlyCosmos

    {"project":"Glycan-GlyCosmos","denotations":[{"id":"T1","span":{"begin":629,"end":635},"obj":"Glycan"},{"id":"T2","span":{"begin":667,"end":673},"obj":"Glycan"},{"id":"T3","span":{"begin":1534,"end":1540},"obj":"Glycan"},{"id":"T4","span":{"begin":1597,"end":1603},"obj":"Glycan"},{"id":"T5","span":{"begin":1716,"end":1722},"obj":"Glycan"}],"attributes":[{"id":"A1","pred":"glycosmos_id","subj":"T1","obj":"https://glycosmos.org/glycans/show/G39738WL"},{"id":"A6","pred":"image","subj":"T1","obj":"https://api.glycosmos.org/wurcs2image/latest/png/binary/G39738WL"},{"id":"A2","pred":"glycosmos_id","subj":"T2","obj":"https://glycosmos.org/glycans/show/G39738WL"},{"id":"A7","pred":"image","subj":"T2","obj":"https://api.glycosmos.org/wurcs2image/latest/png/binary/G39738WL"},{"id":"A3","pred":"glycosmos_id","subj":"T3","obj":"https://glycosmos.org/glycans/show/G39738WL"},{"id":"A8","pred":"image","subj":"T3","obj":"https://api.glycosmos.org/wurcs2image/latest/png/binary/G39738WL"},{"id":"A4","pred":"glycosmos_id","subj":"T4","obj":"https://glycosmos.org/glycans/show/G39738WL"},{"id":"A9","pred":"image","subj":"T4","obj":"https://api.glycosmos.org/wurcs2image/latest/png/binary/G39738WL"},{"id":"A5","pred":"glycosmos_id","subj":"T5","obj":"https://glycosmos.org/glycans/show/G39738WL"},{"id":"A10","pred":"image","subj":"T5","obj":"https://api.glycosmos.org/wurcs2image/latest/png/binary/G39738WL"}],"text":"Novel immunogenicity of Thomsen-Friedenreich disaccharide obtained by a molecular rotation on its carrier linkage.\nThe alpha-anomeric Galbeta1-3GalNAc, called Thomsen-Friedenreich disaccharide (TFD), is overexpressed in epithelial cancer cells by aberrant O-glycosylation. TFD is also the main ligand of Agaricus bisporus lectin (ABL), a reversible noncytotoxic inhibitor of proliferation of epithelial cell lines. In order to obtain anti-TFD antibody response with a fine carbohydrate-binding specificity similar to that of ABL, we designed an immunogen of TFD with a molecular rotation on its carrier linkage that exposes more GalNAc than Gal, since ABL recognizes GalNAc more than Gal in TFD. The synthesis was accomplished by C-6 oxidation of Gal from TFD or its alpha-benzyl derivative (BzlalphaTFD), followed by reductive amination between the C-6 aldehyde yielded and the available amine of protein. Mice immunized with TFD-KLH (keyhole limpet hemocyanin) or BzlalphaTFD-KLH produced antibodies which were then analyzed by ELISA against several target antigens. Both immunogens raised anti-KLH antibody titers; however, TFD-KLH did not raise anti-TFD antibodies showing low TFD immunogenicity. In contrast, BzlalphaTFD-KLH gave much higher anti-TFD antibody response, indicating that benzyl residue helps improve anti-carbohydrate immune response. When IgG and IgM anti-TFD antibodies were analyzed by competitive ELISA using TFD-related carbohydrates as inhibitors, a high specificity to TFD as well as an enhanced binding to GalNAc over Gal were observed. The axial C-4 hydroxyl group of GalNAc interacted with IgG anti-TFD antibody, as evidenced by the lack of inhibitory activity of GlcNAc in contrast to GalNAc. These findings indicate that the anti-TFD antibodies have fine carbohydrate-binding specificity more similar to ABL than to other TFD-binding proteins that stimulate proliferation of epithelial cell lines."}

    GlyCosmos15-HP

    {"project":"GlyCosmos15-HP","denotations":[{"id":"T1","span":{"begin":231,"end":237},"obj":"Phenotype"}],"attributes":[{"id":"A1","pred":"hp_id","subj":"T1","obj":"HP:0002664"}],"text":"Novel immunogenicity of Thomsen-Friedenreich disaccharide obtained by a molecular rotation on its carrier linkage.\nThe alpha-anomeric Galbeta1-3GalNAc, called Thomsen-Friedenreich disaccharide (TFD), is overexpressed in epithelial cancer cells by aberrant O-glycosylation. TFD is also the main ligand of Agaricus bisporus lectin (ABL), a reversible noncytotoxic inhibitor of proliferation of epithelial cell lines. In order to obtain anti-TFD antibody response with a fine carbohydrate-binding specificity similar to that of ABL, we designed an immunogen of TFD with a molecular rotation on its carrier linkage that exposes more GalNAc than Gal, since ABL recognizes GalNAc more than Gal in TFD. The synthesis was accomplished by C-6 oxidation of Gal from TFD or its alpha-benzyl derivative (BzlalphaTFD), followed by reductive amination between the C-6 aldehyde yielded and the available amine of protein. Mice immunized with TFD-KLH (keyhole limpet hemocyanin) or BzlalphaTFD-KLH produced antibodies which were then analyzed by ELISA against several target antigens. Both immunogens raised anti-KLH antibody titers; however, TFD-KLH did not raise anti-TFD antibodies showing low TFD immunogenicity. In contrast, BzlalphaTFD-KLH gave much higher anti-TFD antibody response, indicating that benzyl residue helps improve anti-carbohydrate immune response. When IgG and IgM anti-TFD antibodies were analyzed by competitive ELISA using TFD-related carbohydrates as inhibitors, a high specificity to TFD as well as an enhanced binding to GalNAc over Gal were observed. The axial C-4 hydroxyl group of GalNAc interacted with IgG anti-TFD antibody, as evidenced by the lack of inhibitory activity of GlcNAc in contrast to GalNAc. These findings indicate that the anti-TFD antibodies have fine carbohydrate-binding specificity more similar to ABL than to other TFD-binding proteins that stimulate proliferation of epithelial cell lines."}

    GlyCosmos15-MONDO

    {"project":"GlyCosmos15-MONDO","denotations":[{"id":"T1","span":{"begin":231,"end":237},"obj":"Disease"},{"id":"T2","span":{"begin":330,"end":333},"obj":"Disease"},{"id":"T3","span":{"begin":525,"end":528},"obj":"Disease"},{"id":"T4","span":{"begin":652,"end":655},"obj":"Disease"},{"id":"T5","span":{"begin":1836,"end":1839},"obj":"Disease"}],"attributes":[{"id":"A1","pred":"mondo_id","subj":"T1","obj":"http://purl.obolibrary.org/obo/MONDO_0004992"},{"id":"A2","pred":"mondo_id","subj":"T2","obj":"http://purl.obolibrary.org/obo/MONDO_0008692"},{"id":"A3","pred":"mondo_id","subj":"T3","obj":"http://purl.obolibrary.org/obo/MONDO_0008692"},{"id":"A4","pred":"mondo_id","subj":"T4","obj":"http://purl.obolibrary.org/obo/MONDO_0008692"},{"id":"A5","pred":"mondo_id","subj":"T5","obj":"http://purl.obolibrary.org/obo/MONDO_0008692"}],"text":"Novel immunogenicity of Thomsen-Friedenreich disaccharide obtained by a molecular rotation on its carrier linkage.\nThe alpha-anomeric Galbeta1-3GalNAc, called Thomsen-Friedenreich disaccharide (TFD), is overexpressed in epithelial cancer cells by aberrant O-glycosylation. TFD is also the main ligand of Agaricus bisporus lectin (ABL), a reversible noncytotoxic inhibitor of proliferation of epithelial cell lines. In order to obtain anti-TFD antibody response with a fine carbohydrate-binding specificity similar to that of ABL, we designed an immunogen of TFD with a molecular rotation on its carrier linkage that exposes more GalNAc than Gal, since ABL recognizes GalNAc more than Gal in TFD. The synthesis was accomplished by C-6 oxidation of Gal from TFD or its alpha-benzyl derivative (BzlalphaTFD), followed by reductive amination between the C-6 aldehyde yielded and the available amine of protein. Mice immunized with TFD-KLH (keyhole limpet hemocyanin) or BzlalphaTFD-KLH produced antibodies which were then analyzed by ELISA against several target antigens. Both immunogens raised anti-KLH antibody titers; however, TFD-KLH did not raise anti-TFD antibodies showing low TFD immunogenicity. In contrast, BzlalphaTFD-KLH gave much higher anti-TFD antibody response, indicating that benzyl residue helps improve anti-carbohydrate immune response. When IgG and IgM anti-TFD antibodies were analyzed by competitive ELISA using TFD-related carbohydrates as inhibitors, a high specificity to TFD as well as an enhanced binding to GalNAc over Gal were observed. The axial C-4 hydroxyl group of GalNAc interacted with IgG anti-TFD antibody, as evidenced by the lack of inhibitory activity of GlcNAc in contrast to GalNAc. These findings indicate that the anti-TFD antibodies have fine carbohydrate-binding specificity more similar to ABL than to other TFD-binding proteins that stimulate proliferation of epithelial cell lines."}

    GlyCosmos15-NCBITAXON

    {"project":"GlyCosmos15-NCBITAXON","denotations":[{"id":"T1","span":{"begin":304,"end":321},"obj":"OrganismTaxon"},{"id":"T2","span":{"begin":907,"end":911},"obj":"OrganismTaxon"}],"attributes":[{"id":"A1","pred":"db_id","subj":"T1","obj":"5341"},{"id":"A2","pred":"db_id","subj":"T2","obj":"10088"}],"text":"Novel immunogenicity of Thomsen-Friedenreich disaccharide obtained by a molecular rotation on its carrier linkage.\nThe alpha-anomeric Galbeta1-3GalNAc, called Thomsen-Friedenreich disaccharide (TFD), is overexpressed in epithelial cancer cells by aberrant O-glycosylation. TFD is also the main ligand of Agaricus bisporus lectin (ABL), a reversible noncytotoxic inhibitor of proliferation of epithelial cell lines. In order to obtain anti-TFD antibody response with a fine carbohydrate-binding specificity similar to that of ABL, we designed an immunogen of TFD with a molecular rotation on its carrier linkage that exposes more GalNAc than Gal, since ABL recognizes GalNAc more than Gal in TFD. The synthesis was accomplished by C-6 oxidation of Gal from TFD or its alpha-benzyl derivative (BzlalphaTFD), followed by reductive amination between the C-6 aldehyde yielded and the available amine of protein. Mice immunized with TFD-KLH (keyhole limpet hemocyanin) or BzlalphaTFD-KLH produced antibodies which were then analyzed by ELISA against several target antigens. Both immunogens raised anti-KLH antibody titers; however, TFD-KLH did not raise anti-TFD antibodies showing low TFD immunogenicity. In contrast, BzlalphaTFD-KLH gave much higher anti-TFD antibody response, indicating that benzyl residue helps improve anti-carbohydrate immune response. When IgG and IgM anti-TFD antibodies were analyzed by competitive ELISA using TFD-related carbohydrates as inhibitors, a high specificity to TFD as well as an enhanced binding to GalNAc over Gal were observed. The axial C-4 hydroxyl group of GalNAc interacted with IgG anti-TFD antibody, as evidenced by the lack of inhibitory activity of GlcNAc in contrast to GalNAc. These findings indicate that the anti-TFD antibodies have fine carbohydrate-binding specificity more similar to ABL than to other TFD-binding proteins that stimulate proliferation of epithelial cell lines."}

    GlyCosmos15-CL

    {"project":"GlyCosmos15-CL","denotations":[{"id":"T1","span":{"begin":231,"end":243},"obj":"Cell"},{"id":"T2","span":{"begin":392,"end":407},"obj":"Cell"},{"id":"T3","span":{"begin":1907,"end":1922},"obj":"Cell"}],"attributes":[{"id":"A1","pred":"cl_id","subj":"T1","obj":"http://purl.obolibrary.org/obo/CL:0001064"},{"id":"A2","pred":"cl_id","subj":"T2","obj":"http://purl.obolibrary.org/obo/CL:0000066"},{"id":"A3","pred":"cl_id","subj":"T3","obj":"http://purl.obolibrary.org/obo/CL:0000066"}],"text":"Novel immunogenicity of Thomsen-Friedenreich disaccharide obtained by a molecular rotation on its carrier linkage.\nThe alpha-anomeric Galbeta1-3GalNAc, called Thomsen-Friedenreich disaccharide (TFD), is overexpressed in epithelial cancer cells by aberrant O-glycosylation. TFD is also the main ligand of Agaricus bisporus lectin (ABL), a reversible noncytotoxic inhibitor of proliferation of epithelial cell lines. In order to obtain anti-TFD antibody response with a fine carbohydrate-binding specificity similar to that of ABL, we designed an immunogen of TFD with a molecular rotation on its carrier linkage that exposes more GalNAc than Gal, since ABL recognizes GalNAc more than Gal in TFD. The synthesis was accomplished by C-6 oxidation of Gal from TFD or its alpha-benzyl derivative (BzlalphaTFD), followed by reductive amination between the C-6 aldehyde yielded and the available amine of protein. Mice immunized with TFD-KLH (keyhole limpet hemocyanin) or BzlalphaTFD-KLH produced antibodies which were then analyzed by ELISA against several target antigens. Both immunogens raised anti-KLH antibody titers; however, TFD-KLH did not raise anti-TFD antibodies showing low TFD immunogenicity. In contrast, BzlalphaTFD-KLH gave much higher anti-TFD antibody response, indicating that benzyl residue helps improve anti-carbohydrate immune response. When IgG and IgM anti-TFD antibodies were analyzed by competitive ELISA using TFD-related carbohydrates as inhibitors, a high specificity to TFD as well as an enhanced binding to GalNAc over Gal were observed. The axial C-4 hydroxyl group of GalNAc interacted with IgG anti-TFD antibody, as evidenced by the lack of inhibitory activity of GlcNAc in contrast to GalNAc. These findings indicate that the anti-TFD antibodies have fine carbohydrate-binding specificity more similar to ABL than to other TFD-binding proteins that stimulate proliferation of epithelial cell lines."}

    GlyCosmos15-UBERON

    {"project":"GlyCosmos15-UBERON","denotations":[{"id":"T1","span":{"begin":392,"end":407},"obj":"Body_part"},{"id":"T2","span":{"begin":1907,"end":1922},"obj":"Body_part"}],"attributes":[{"id":"A1","pred":"uberon_id","subj":"T1","obj":"http://purl.obolibrary.org/obo/CL_0000066"},{"id":"A2","pred":"uberon_id","subj":"T2","obj":"http://purl.obolibrary.org/obo/CL_0000066"}],"text":"Novel immunogenicity of Thomsen-Friedenreich disaccharide obtained by a molecular rotation on its carrier linkage.\nThe alpha-anomeric Galbeta1-3GalNAc, called Thomsen-Friedenreich disaccharide (TFD), is overexpressed in epithelial cancer cells by aberrant O-glycosylation. TFD is also the main ligand of Agaricus bisporus lectin (ABL), a reversible noncytotoxic inhibitor of proliferation of epithelial cell lines. In order to obtain anti-TFD antibody response with a fine carbohydrate-binding specificity similar to that of ABL, we designed an immunogen of TFD with a molecular rotation on its carrier linkage that exposes more GalNAc than Gal, since ABL recognizes GalNAc more than Gal in TFD. The synthesis was accomplished by C-6 oxidation of Gal from TFD or its alpha-benzyl derivative (BzlalphaTFD), followed by reductive amination between the C-6 aldehyde yielded and the available amine of protein. Mice immunized with TFD-KLH (keyhole limpet hemocyanin) or BzlalphaTFD-KLH produced antibodies which were then analyzed by ELISA against several target antigens. Both immunogens raised anti-KLH antibody titers; however, TFD-KLH did not raise anti-TFD antibodies showing low TFD immunogenicity. In contrast, BzlalphaTFD-KLH gave much higher anti-TFD antibody response, indicating that benzyl residue helps improve anti-carbohydrate immune response. When IgG and IgM anti-TFD antibodies were analyzed by competitive ELISA using TFD-related carbohydrates as inhibitors, a high specificity to TFD as well as an enhanced binding to GalNAc over Gal were observed. The axial C-4 hydroxyl group of GalNAc interacted with IgG anti-TFD antibody, as evidenced by the lack of inhibitory activity of GlcNAc in contrast to GalNAc. These findings indicate that the anti-TFD antibodies have fine carbohydrate-binding specificity more similar to ABL than to other TFD-binding proteins that stimulate proliferation of epithelial cell lines."}

    sentences

    {"project":"sentences","denotations":[{"id":"TextSentencer_T1","span":{"begin":0,"end":114},"obj":"Sentence"},{"id":"TextSentencer_T2","span":{"begin":115,"end":272},"obj":"Sentence"},{"id":"TextSentencer_T3","span":{"begin":273,"end":414},"obj":"Sentence"},{"id":"TextSentencer_T4","span":{"begin":415,"end":695},"obj":"Sentence"},{"id":"TextSentencer_T5","span":{"begin":696,"end":906},"obj":"Sentence"},{"id":"TextSentencer_T6","span":{"begin":907,"end":1068},"obj":"Sentence"},{"id":"TextSentencer_T7","span":{"begin":1069,"end":1200},"obj":"Sentence"},{"id":"TextSentencer_T8","span":{"begin":1201,"end":1354},"obj":"Sentence"},{"id":"TextSentencer_T9","span":{"begin":1355,"end":1564},"obj":"Sentence"},{"id":"TextSentencer_T10","span":{"begin":1565,"end":1723},"obj":"Sentence"},{"id":"TextSentencer_T11","span":{"begin":1724,"end":1929},"obj":"Sentence"},{"id":"T1","span":{"begin":0,"end":114},"obj":"Sentence"},{"id":"T2","span":{"begin":115,"end":272},"obj":"Sentence"},{"id":"T3","span":{"begin":273,"end":414},"obj":"Sentence"},{"id":"T4","span":{"begin":415,"end":695},"obj":"Sentence"},{"id":"T5","span":{"begin":696,"end":906},"obj":"Sentence"},{"id":"T6","span":{"begin":907,"end":1068},"obj":"Sentence"},{"id":"T7","span":{"begin":1069,"end":1200},"obj":"Sentence"},{"id":"T8","span":{"begin":1201,"end":1354},"obj":"Sentence"},{"id":"T9","span":{"begin":1355,"end":1564},"obj":"Sentence"},{"id":"T10","span":{"begin":1565,"end":1723},"obj":"Sentence"},{"id":"T11","span":{"begin":1724,"end":1929},"obj":"Sentence"},{"id":"T1","span":{"begin":0,"end":114},"obj":"Sentence"},{"id":"T2","span":{"begin":115,"end":272},"obj":"Sentence"},{"id":"T3","span":{"begin":273,"end":414},"obj":"Sentence"},{"id":"T4","span":{"begin":415,"end":695},"obj":"Sentence"},{"id":"T5","span":{"begin":696,"end":906},"obj":"Sentence"},{"id":"T6","span":{"begin":907,"end":1068},"obj":"Sentence"},{"id":"T7","span":{"begin":1069,"end":1200},"obj":"Sentence"},{"id":"T8","span":{"begin":1201,"end":1354},"obj":"Sentence"},{"id":"T9","span":{"begin":1355,"end":1564},"obj":"Sentence"},{"id":"T10","span":{"begin":1565,"end":1723},"obj":"Sentence"},{"id":"T11","span":{"begin":1724,"end":1929},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"Novel immunogenicity of Thomsen-Friedenreich disaccharide obtained by a molecular rotation on its carrier linkage.\nThe alpha-anomeric Galbeta1-3GalNAc, called Thomsen-Friedenreich disaccharide (TFD), is overexpressed in epithelial cancer cells by aberrant O-glycosylation. TFD is also the main ligand of Agaricus bisporus lectin (ABL), a reversible noncytotoxic inhibitor of proliferation of epithelial cell lines. In order to obtain anti-TFD antibody response with a fine carbohydrate-binding specificity similar to that of ABL, we designed an immunogen of TFD with a molecular rotation on its carrier linkage that exposes more GalNAc than Gal, since ABL recognizes GalNAc more than Gal in TFD. The synthesis was accomplished by C-6 oxidation of Gal from TFD or its alpha-benzyl derivative (BzlalphaTFD), followed by reductive amination between the C-6 aldehyde yielded and the available amine of protein. Mice immunized with TFD-KLH (keyhole limpet hemocyanin) or BzlalphaTFD-KLH produced antibodies which were then analyzed by ELISA against several target antigens. Both immunogens raised anti-KLH antibody titers; however, TFD-KLH did not raise anti-TFD antibodies showing low TFD immunogenicity. In contrast, BzlalphaTFD-KLH gave much higher anti-TFD antibody response, indicating that benzyl residue helps improve anti-carbohydrate immune response. When IgG and IgM anti-TFD antibodies were analyzed by competitive ELISA using TFD-related carbohydrates as inhibitors, a high specificity to TFD as well as an enhanced binding to GalNAc over Gal were observed. The axial C-4 hydroxyl group of GalNAc interacted with IgG anti-TFD antibody, as evidenced by the lack of inhibitory activity of GlcNAc in contrast to GalNAc. These findings indicate that the anti-TFD antibodies have fine carbohydrate-binding specificity more similar to ABL than to other TFD-binding proteins that stimulate proliferation of epithelial cell lines."}

    GlyCosmos15-Sentences

    {"project":"GlyCosmos15-Sentences","blocks":[{"id":"T1","span":{"begin":0,"end":114},"obj":"Sentence"},{"id":"T2","span":{"begin":115,"end":272},"obj":"Sentence"},{"id":"T3","span":{"begin":273,"end":414},"obj":"Sentence"},{"id":"T4","span":{"begin":415,"end":695},"obj":"Sentence"},{"id":"T5","span":{"begin":696,"end":906},"obj":"Sentence"},{"id":"T6","span":{"begin":907,"end":1068},"obj":"Sentence"},{"id":"T7","span":{"begin":1069,"end":1200},"obj":"Sentence"},{"id":"T8","span":{"begin":1201,"end":1354},"obj":"Sentence"},{"id":"T9","span":{"begin":1355,"end":1564},"obj":"Sentence"},{"id":"T10","span":{"begin":1565,"end":1723},"obj":"Sentence"},{"id":"T11","span":{"begin":1724,"end":1929},"obj":"Sentence"}],"text":"Novel immunogenicity of Thomsen-Friedenreich disaccharide obtained by a molecular rotation on its carrier linkage.\nThe alpha-anomeric Galbeta1-3GalNAc, called Thomsen-Friedenreich disaccharide (TFD), is overexpressed in epithelial cancer cells by aberrant O-glycosylation. TFD is also the main ligand of Agaricus bisporus lectin (ABL), a reversible noncytotoxic inhibitor of proliferation of epithelial cell lines. In order to obtain anti-TFD antibody response with a fine carbohydrate-binding specificity similar to that of ABL, we designed an immunogen of TFD with a molecular rotation on its carrier linkage that exposes more GalNAc than Gal, since ABL recognizes GalNAc more than Gal in TFD. The synthesis was accomplished by C-6 oxidation of Gal from TFD or its alpha-benzyl derivative (BzlalphaTFD), followed by reductive amination between the C-6 aldehyde yielded and the available amine of protein. Mice immunized with TFD-KLH (keyhole limpet hemocyanin) or BzlalphaTFD-KLH produced antibodies which were then analyzed by ELISA against several target antigens. Both immunogens raised anti-KLH antibody titers; however, TFD-KLH did not raise anti-TFD antibodies showing low TFD immunogenicity. In contrast, BzlalphaTFD-KLH gave much higher anti-TFD antibody response, indicating that benzyl residue helps improve anti-carbohydrate immune response. When IgG and IgM anti-TFD antibodies were analyzed by competitive ELISA using TFD-related carbohydrates as inhibitors, a high specificity to TFD as well as an enhanced binding to GalNAc over Gal were observed. The axial C-4 hydroxyl group of GalNAc interacted with IgG anti-TFD antibody, as evidenced by the lack of inhibitory activity of GlcNAc in contrast to GalNAc. These findings indicate that the anti-TFD antibodies have fine carbohydrate-binding specificity more similar to ABL than to other TFD-binding proteins that stimulate proliferation of epithelial cell lines."}

    GlyCosmos15-Glycan

    {"project":"GlyCosmos15-Glycan","denotations":[{"id":"T1","span":{"begin":629,"end":635},"obj":"Glycan"},{"id":"T2","span":{"begin":667,"end":673},"obj":"Glycan"},{"id":"T3","span":{"begin":1534,"end":1540},"obj":"Glycan"},{"id":"T4","span":{"begin":1597,"end":1603},"obj":"Glycan"},{"id":"T5","span":{"begin":1716,"end":1722},"obj":"Glycan"}],"attributes":[{"id":"A1","pred":"glycosmos_id","subj":"T1","obj":"https://glycosmos.org/glycans/show/G39738WL"},{"id":"A6","pred":"image","subj":"T1","obj":"https://api.glycosmos.org/wurcs2image/latest/png/binary/G39738WL"},{"id":"A2","pred":"glycosmos_id","subj":"T2","obj":"https://glycosmos.org/glycans/show/G39738WL"},{"id":"A7","pred":"image","subj":"T2","obj":"https://api.glycosmos.org/wurcs2image/latest/png/binary/G39738WL"},{"id":"A3","pred":"glycosmos_id","subj":"T3","obj":"https://glycosmos.org/glycans/show/G39738WL"},{"id":"A8","pred":"image","subj":"T3","obj":"https://api.glycosmos.org/wurcs2image/latest/png/binary/G39738WL"},{"id":"A4","pred":"glycosmos_id","subj":"T4","obj":"https://glycosmos.org/glycans/show/G39738WL"},{"id":"A9","pred":"image","subj":"T4","obj":"https://api.glycosmos.org/wurcs2image/latest/png/binary/G39738WL"},{"id":"A5","pred":"glycosmos_id","subj":"T5","obj":"https://glycosmos.org/glycans/show/G39738WL"},{"id":"A10","pred":"image","subj":"T5","obj":"https://api.glycosmos.org/wurcs2image/latest/png/binary/G39738WL"}],"text":"Novel immunogenicity of Thomsen-Friedenreich disaccharide obtained by a molecular rotation on its carrier linkage.\nThe alpha-anomeric Galbeta1-3GalNAc, called Thomsen-Friedenreich disaccharide (TFD), is overexpressed in epithelial cancer cells by aberrant O-glycosylation. TFD is also the main ligand of Agaricus bisporus lectin (ABL), a reversible noncytotoxic inhibitor of proliferation of epithelial cell lines. In order to obtain anti-TFD antibody response with a fine carbohydrate-binding specificity similar to that of ABL, we designed an immunogen of TFD with a molecular rotation on its carrier linkage that exposes more GalNAc than Gal, since ABL recognizes GalNAc more than Gal in TFD. The synthesis was accomplished by C-6 oxidation of Gal from TFD or its alpha-benzyl derivative (BzlalphaTFD), followed by reductive amination between the C-6 aldehyde yielded and the available amine of protein. Mice immunized with TFD-KLH (keyhole limpet hemocyanin) or BzlalphaTFD-KLH produced antibodies which were then analyzed by ELISA against several target antigens. Both immunogens raised anti-KLH antibody titers; however, TFD-KLH did not raise anti-TFD antibodies showing low TFD immunogenicity. In contrast, BzlalphaTFD-KLH gave much higher anti-TFD antibody response, indicating that benzyl residue helps improve anti-carbohydrate immune response. When IgG and IgM anti-TFD antibodies were analyzed by competitive ELISA using TFD-related carbohydrates as inhibitors, a high specificity to TFD as well as an enhanced binding to GalNAc over Gal were observed. The axial C-4 hydroxyl group of GalNAc interacted with IgG anti-TFD antibody, as evidenced by the lack of inhibitory activity of GlcNAc in contrast to GalNAc. These findings indicate that the anti-TFD antibodies have fine carbohydrate-binding specificity more similar to ABL than to other TFD-binding proteins that stimulate proliferation of epithelial cell lines."}

    GlyCosmos15-Lectin-Jamboree

    {"project":"GlyCosmos15-Lectin-Jamboree","denotations":[{"id":"T1","span":{"begin":330,"end":333},"obj":"Lectin"},{"id":"T2","span":{"begin":525,"end":528},"obj":"Lectin"},{"id":"T3","span":{"begin":652,"end":655},"obj":"Lectin"},{"id":"T4","span":{"begin":1836,"end":1839},"obj":"Lectin"}],"attributes":[{"id":"A1","pred":"glycosmos_id","subj":"T1","obj":"GL_001756"},{"id":"A2","pred":"glycosmos_id","subj":"T2","obj":"GL_001756"},{"id":"A3","pred":"glycosmos_id","subj":"T3","obj":"GL_001756"},{"id":"A4","pred":"glycosmos_id","subj":"T4","obj":"GL_001756"}],"text":"Novel immunogenicity of Thomsen-Friedenreich disaccharide obtained by a molecular rotation on its carrier linkage.\nThe alpha-anomeric Galbeta1-3GalNAc, called Thomsen-Friedenreich disaccharide (TFD), is overexpressed in epithelial cancer cells by aberrant O-glycosylation. TFD is also the main ligand of Agaricus bisporus lectin (ABL), a reversible noncytotoxic inhibitor of proliferation of epithelial cell lines. In order to obtain anti-TFD antibody response with a fine carbohydrate-binding specificity similar to that of ABL, we designed an immunogen of TFD with a molecular rotation on its carrier linkage that exposes more GalNAc than Gal, since ABL recognizes GalNAc more than Gal in TFD. The synthesis was accomplished by C-6 oxidation of Gal from TFD or its alpha-benzyl derivative (BzlalphaTFD), followed by reductive amination between the C-6 aldehyde yielded and the available amine of protein. Mice immunized with TFD-KLH (keyhole limpet hemocyanin) or BzlalphaTFD-KLH produced antibodies which were then analyzed by ELISA against several target antigens. Both immunogens raised anti-KLH antibody titers; however, TFD-KLH did not raise anti-TFD antibodies showing low TFD immunogenicity. In contrast, BzlalphaTFD-KLH gave much higher anti-TFD antibody response, indicating that benzyl residue helps improve anti-carbohydrate immune response. When IgG and IgM anti-TFD antibodies were analyzed by competitive ELISA using TFD-related carbohydrates as inhibitors, a high specificity to TFD as well as an enhanced binding to GalNAc over Gal were observed. The axial C-4 hydroxyl group of GalNAc interacted with IgG anti-TFD antibody, as evidenced by the lack of inhibitory activity of GlcNAc in contrast to GalNAc. These findings indicate that the anti-TFD antibodies have fine carbohydrate-binding specificity more similar to ABL than to other TFD-binding proteins that stimulate proliferation of epithelial cell lines."}

    Lectin-Jamboree-small

    {"project":"Lectin-Jamboree-small","denotations":[{"id":"T1","span":{"begin":330,"end":333},"obj":"Lectin"},{"id":"T2","span":{"begin":525,"end":528},"obj":"Lectin"},{"id":"T3","span":{"begin":652,"end":655},"obj":"Lectin"},{"id":"T4","span":{"begin":1836,"end":1839},"obj":"Lectin"}],"attributes":[{"id":"A1","pred":"glycosmos_id","subj":"T1","obj":"GL_001756"},{"id":"A2","pred":"glycosmos_id","subj":"T2","obj":"GL_001756"},{"id":"A3","pred":"glycosmos_id","subj":"T3","obj":"GL_001756"},{"id":"A4","pred":"glycosmos_id","subj":"T4","obj":"GL_001756"}],"namespaces":[{"prefix":"_base","uri":"https://glycosmos.org/lectins/"}],"text":"Novel immunogenicity of Thomsen-Friedenreich disaccharide obtained by a molecular rotation on its carrier linkage.\nThe alpha-anomeric Galbeta1-3GalNAc, called Thomsen-Friedenreich disaccharide (TFD), is overexpressed in epithelial cancer cells by aberrant O-glycosylation. TFD is also the main ligand of Agaricus bisporus lectin (ABL), a reversible noncytotoxic inhibitor of proliferation of epithelial cell lines. In order to obtain anti-TFD antibody response with a fine carbohydrate-binding specificity similar to that of ABL, we designed an immunogen of TFD with a molecular rotation on its carrier linkage that exposes more GalNAc than Gal, since ABL recognizes GalNAc more than Gal in TFD. The synthesis was accomplished by C-6 oxidation of Gal from TFD or its alpha-benzyl derivative (BzlalphaTFD), followed by reductive amination between the C-6 aldehyde yielded and the available amine of protein. Mice immunized with TFD-KLH (keyhole limpet hemocyanin) or BzlalphaTFD-KLH produced antibodies which were then analyzed by ELISA against several target antigens. Both immunogens raised anti-KLH antibody titers; however, TFD-KLH did not raise anti-TFD antibodies showing low TFD immunogenicity. In contrast, BzlalphaTFD-KLH gave much higher anti-TFD antibody response, indicating that benzyl residue helps improve anti-carbohydrate immune response. When IgG and IgM anti-TFD antibodies were analyzed by competitive ELISA using TFD-related carbohydrates as inhibitors, a high specificity to TFD as well as an enhanced binding to GalNAc over Gal were observed. The axial C-4 hydroxyl group of GalNAc interacted with IgG anti-TFD antibody, as evidenced by the lack of inhibitory activity of GlcNAc in contrast to GalNAc. These findings indicate that the anti-TFD antibodies have fine carbohydrate-binding specificity more similar to ABL than to other TFD-binding proteins that stimulate proliferation of epithelial cell lines."}

    Lectin-Jamboree

    {"project":"Lectin-Jamboree","denotations":[{"id":"T1","span":{"begin":322,"end":328},"obj":"lectin"}],"text":"Novel immunogenicity of Thomsen-Friedenreich disaccharide obtained by a molecular rotation on its carrier linkage.\nThe alpha-anomeric Galbeta1-3GalNAc, called Thomsen-Friedenreich disaccharide (TFD), is overexpressed in epithelial cancer cells by aberrant O-glycosylation. TFD is also the main ligand of Agaricus bisporus lectin (ABL), a reversible noncytotoxic inhibitor of proliferation of epithelial cell lines. In order to obtain anti-TFD antibody response with a fine carbohydrate-binding specificity similar to that of ABL, we designed an immunogen of TFD with a molecular rotation on its carrier linkage that exposes more GalNAc than Gal, since ABL recognizes GalNAc more than Gal in TFD. The synthesis was accomplished by C-6 oxidation of Gal from TFD or its alpha-benzyl derivative (BzlalphaTFD), followed by reductive amination between the C-6 aldehyde yielded and the available amine of protein. Mice immunized with TFD-KLH (keyhole limpet hemocyanin) or BzlalphaTFD-KLH produced antibodies which were then analyzed by ELISA against several target antigens. Both immunogens raised anti-KLH antibody titers; however, TFD-KLH did not raise anti-TFD antibodies showing low TFD immunogenicity. In contrast, BzlalphaTFD-KLH gave much higher anti-TFD antibody response, indicating that benzyl residue helps improve anti-carbohydrate immune response. When IgG and IgM anti-TFD antibodies were analyzed by competitive ELISA using TFD-related carbohydrates as inhibitors, a high specificity to TFD as well as an enhanced binding to GalNAc over Gal were observed. The axial C-4 hydroxyl group of GalNAc interacted with IgG anti-TFD antibody, as evidenced by the lack of inhibitory activity of GlcNAc in contrast to GalNAc. These findings indicate that the anti-TFD antibodies have fine carbohydrate-binding specificity more similar to ABL than to other TFD-binding proteins that stimulate proliferation of epithelial cell lines."}

    Lectin-Jamboree-Sentence

    {"project":"Lectin-Jamboree-Sentence","blocks":[{"id":"T1","span":{"begin":0,"end":114},"obj":"Sentence"},{"id":"T2","span":{"begin":115,"end":272},"obj":"Sentence"},{"id":"T3","span":{"begin":273,"end":414},"obj":"Sentence"},{"id":"T4","span":{"begin":415,"end":695},"obj":"Sentence"},{"id":"T5","span":{"begin":696,"end":906},"obj":"Sentence"},{"id":"T6","span":{"begin":907,"end":1068},"obj":"Sentence"},{"id":"T7","span":{"begin":1069,"end":1200},"obj":"Sentence"},{"id":"T8","span":{"begin":1201,"end":1354},"obj":"Sentence"},{"id":"T9","span":{"begin":1355,"end":1564},"obj":"Sentence"},{"id":"T10","span":{"begin":1565,"end":1723},"obj":"Sentence"},{"id":"T11","span":{"begin":1724,"end":1929},"obj":"Sentence"}],"text":"Novel immunogenicity of Thomsen-Friedenreich disaccharide obtained by a molecular rotation on its carrier linkage.\nThe alpha-anomeric Galbeta1-3GalNAc, called Thomsen-Friedenreich disaccharide (TFD), is overexpressed in epithelial cancer cells by aberrant O-glycosylation. TFD is also the main ligand of Agaricus bisporus lectin (ABL), a reversible noncytotoxic inhibitor of proliferation of epithelial cell lines. In order to obtain anti-TFD antibody response with a fine carbohydrate-binding specificity similar to that of ABL, we designed an immunogen of TFD with a molecular rotation on its carrier linkage that exposes more GalNAc than Gal, since ABL recognizes GalNAc more than Gal in TFD. The synthesis was accomplished by C-6 oxidation of Gal from TFD or its alpha-benzyl derivative (BzlalphaTFD), followed by reductive amination between the C-6 aldehyde yielded and the available amine of protein. Mice immunized with TFD-KLH (keyhole limpet hemocyanin) or BzlalphaTFD-KLH produced antibodies which were then analyzed by ELISA against several target antigens. Both immunogens raised anti-KLH antibody titers; however, TFD-KLH did not raise anti-TFD antibodies showing low TFD immunogenicity. In contrast, BzlalphaTFD-KLH gave much higher anti-TFD antibody response, indicating that benzyl residue helps improve anti-carbohydrate immune response. When IgG and IgM anti-TFD antibodies were analyzed by competitive ELISA using TFD-related carbohydrates as inhibitors, a high specificity to TFD as well as an enhanced binding to GalNAc over Gal were observed. The axial C-4 hydroxyl group of GalNAc interacted with IgG anti-TFD antibody, as evidenced by the lack of inhibitory activity of GlcNAc in contrast to GalNAc. These findings indicate that the anti-TFD antibodies have fine carbohydrate-binding specificity more similar to ABL than to other TFD-binding proteins that stimulate proliferation of epithelial cell lines."}

    NCBITAXON

    {"project":"NCBITAXON","denotations":[{"id":"T1","span":{"begin":304,"end":321},"obj":"OrganismTaxon"},{"id":"T2","span":{"begin":907,"end":911},"obj":"OrganismTaxon"}],"attributes":[{"id":"A1","pred":"db_id","subj":"T1","obj":"5341"},{"id":"A2","pred":"db_id","subj":"T2","obj":"10088"}],"text":"Novel immunogenicity of Thomsen-Friedenreich disaccharide obtained by a molecular rotation on its carrier linkage.\nThe alpha-anomeric Galbeta1-3GalNAc, called Thomsen-Friedenreich disaccharide (TFD), is overexpressed in epithelial cancer cells by aberrant O-glycosylation. TFD is also the main ligand of Agaricus bisporus lectin (ABL), a reversible noncytotoxic inhibitor of proliferation of epithelial cell lines. In order to obtain anti-TFD antibody response with a fine carbohydrate-binding specificity similar to that of ABL, we designed an immunogen of TFD with a molecular rotation on its carrier linkage that exposes more GalNAc than Gal, since ABL recognizes GalNAc more than Gal in TFD. The synthesis was accomplished by C-6 oxidation of Gal from TFD or its alpha-benzyl derivative (BzlalphaTFD), followed by reductive amination between the C-6 aldehyde yielded and the available amine of protein. Mice immunized with TFD-KLH (keyhole limpet hemocyanin) or BzlalphaTFD-KLH produced antibodies which were then analyzed by ELISA against several target antigens. Both immunogens raised anti-KLH antibody titers; however, TFD-KLH did not raise anti-TFD antibodies showing low TFD immunogenicity. In contrast, BzlalphaTFD-KLH gave much higher anti-TFD antibody response, indicating that benzyl residue helps improve anti-carbohydrate immune response. When IgG and IgM anti-TFD antibodies were analyzed by competitive ELISA using TFD-related carbohydrates as inhibitors, a high specificity to TFD as well as an enhanced binding to GalNAc over Gal were observed. The axial C-4 hydroxyl group of GalNAc interacted with IgG anti-TFD antibody, as evidenced by the lack of inhibitory activity of GlcNAc in contrast to GalNAc. These findings indicate that the anti-TFD antibodies have fine carbohydrate-binding specificity more similar to ABL than to other TFD-binding proteins that stimulate proliferation of epithelial cell lines."}

    Anatomy-UBERON

    {"project":"Anatomy-UBERON","denotations":[{"id":"T1","span":{"begin":392,"end":407},"obj":"Body_part"},{"id":"T2","span":{"begin":1907,"end":1922},"obj":"Body_part"}],"attributes":[{"id":"A1","pred":"uberon_id","subj":"T1","obj":"http://purl.obolibrary.org/obo/CL_0000066"},{"id":"A2","pred":"uberon_id","subj":"T2","obj":"http://purl.obolibrary.org/obo/CL_0000066"}],"text":"Novel immunogenicity of Thomsen-Friedenreich disaccharide obtained by a molecular rotation on its carrier linkage.\nThe alpha-anomeric Galbeta1-3GalNAc, called Thomsen-Friedenreich disaccharide (TFD), is overexpressed in epithelial cancer cells by aberrant O-glycosylation. TFD is also the main ligand of Agaricus bisporus lectin (ABL), a reversible noncytotoxic inhibitor of proliferation of epithelial cell lines. In order to obtain anti-TFD antibody response with a fine carbohydrate-binding specificity similar to that of ABL, we designed an immunogen of TFD with a molecular rotation on its carrier linkage that exposes more GalNAc than Gal, since ABL recognizes GalNAc more than Gal in TFD. The synthesis was accomplished by C-6 oxidation of Gal from TFD or its alpha-benzyl derivative (BzlalphaTFD), followed by reductive amination between the C-6 aldehyde yielded and the available amine of protein. Mice immunized with TFD-KLH (keyhole limpet hemocyanin) or BzlalphaTFD-KLH produced antibodies which were then analyzed by ELISA against several target antigens. Both immunogens raised anti-KLH antibody titers; however, TFD-KLH did not raise anti-TFD antibodies showing low TFD immunogenicity. In contrast, BzlalphaTFD-KLH gave much higher anti-TFD antibody response, indicating that benzyl residue helps improve anti-carbohydrate immune response. When IgG and IgM anti-TFD antibodies were analyzed by competitive ELISA using TFD-related carbohydrates as inhibitors, a high specificity to TFD as well as an enhanced binding to GalNAc over Gal were observed. The axial C-4 hydroxyl group of GalNAc interacted with IgG anti-TFD antibody, as evidenced by the lack of inhibitory activity of GlcNAc in contrast to GalNAc. These findings indicate that the anti-TFD antibodies have fine carbohydrate-binding specificity more similar to ABL than to other TFD-binding proteins that stimulate proliferation of epithelial cell lines."}